



Patent  
Office

PCT/GB 007 007 77

RECEIVED 27 SEP 2000

WIPG The Patent Office

Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QC

**DOCUMENT DE  
PRIORITE**

PRESENT OF TRANSMIS  
CONFORMEMENT AVEC LE  
ARTICLE 1

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

*Paula Gersy*

Dated

31 AUG 2000



# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference SJK:BP5795950

2. Patent application number

**9920745.8**

3. Full name, address and postcode of the or of each applicant (underline all surnames)

THE UNIVERSITY OF BUCKINGHAM  
HUNTER STREET  
BUCKINGHAM  
MK18 1EG  
GB

Patents ADP number (if you know it)

772297700

If the applicant is a corporate body, give the country/state of its incorporation

GB

(see continuation sheet)

4. Title of the invention

METHODS AND COMPOSITIONS RELATING TO BODY WEIGHT  
AND EATING DISORDERS

5. Name of your agent (if you have one)

MEWBURN ELLIS

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

YORK HOUSE  
23 KINGSWAY  
LONDON  
WC2B 6HP

Patents ADP number (if you know it)

109006 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day month year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day month year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if

YES

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body
- See note (d))

# Patents Form 1/77

9. Enter the number of sheets for each of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 1

Description 90 /

Claim(s) 7 / *R*

Abstract 0

Drawing(s) 33 + 33 /

10. If you are also filing any of the following, state how many against each item

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents (Please specify) 0

11.

I/We request the grant of a patent on the basis of this application.

Signature

*Simon J. Kiddle*

Date

1 September 1999

12. Name and daytime telephone number of person to contact in the United Kingdom

SIMON J. KIDDLE

020 7240 4405

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.



Request for grant of a patent

The Patent Office

CONTINUATION SHEET

---

3. Full name, address and postcode of the or of  
each applicant (*underline all surnames*)

UNIVERSITY OF GENEVA  
1 RUE MICHEL SERVET  
CH1211  
GENEVA 4  
SWITZERLAND

768832804

720

ADP No:

State of incorporation: SWITZERLAND



## Methods and Compositions Relating to Body Weight and Eating Disorders

### Field of the Invention

The present invention relates to methods and compositions relating to body weight disorders and eating disorders in conditions such as obesity. Specifically, the present invention identifies and describes proteins that are differentially expressed in body weight and/or eating disordered states relative to their expression in normal or non-body weight disordered states and in particular identifies and describes proteins associated with the regulation of appetite and body weight. Further, the present invention identifies and describes proteins via their ability to interact with gene products involved in the regulation of body weight and appetite. Still further, the present invention provides methods, particularly experimental paradigms for the identification of differentially expressed proteins that are potential molecular targets for compounds to treat body weight and/or eating disorders including, but not limited to, obesity. Still further, the present invention provides methods for the identification and therapeutic use of compounds for the treatment of body weight and/or eating disorders including, but not limited to, obesity.

### Background of the Invention

Body weight disorders, including eating disorders, are one of the major public health problems in all industrialised countries and is a growing problem in countries undergoing rapid acculturation. Obesity, the most prevalent of eating disorders, is the most common nutritional disorder in the Western world and can have a prevalence of up to 50% in middle-aged and elderly populations. However, it is also an increasing problem.

in children. Other weight disorders, such as anorexia nervosa and bulimia nervosa are also serious health risks and affect approximately 0.2% of the population, particularly female, in Western countries. Anorexia and cachexia are major features of other diseases such as cancer, AIDS and trauma.

Obesity, defined as an excess body fat relative to lean body mass, also contributes to many other diseases. For example, obesity is responsible for the increased incidence of diseases such as coronary artery disease, stroke and non-insulin dependent diabetes. Obesity is not merely a behavioural problem, i.e. the result of voluntary hyperphagia. Rather, the differential body composition observed between obese and non-obese subjects results from differences in both metabolism and neurological/metabolic interactions. These differences are to some extent genetically inherited but the nature of the gene products that control body weight and body composition are unknown. Attempts to identify protein molecules involved in the control of body weight have been largely empiric and the nature of the mechanisms by which body composition and/or substrate flux are monitored have not yet been identified.

The epidemiology of obesity strongly shows that the disorder exhibits inherited characteristics (Stunkard, 1990, N. Eng. J. Med. 322: 1483). Moll et al., have reported that, in many populations, obesity seems to be controlled by a few genetic loci (Moll et al., 1991, Am. J. Hum. Gen. 49: 1243). In addition human twin studies strongly suggest a substantial genetic basis in the control of body weight, with estimates of heritability of 80-90% (Simopoulos, A.P. & Childs, B., eds., 1989, in "Genetic Variation and Nutrition in Obesity", World

Journal of Nutrition and Biochemistry 33, P. Farber, Basel, Switzerland; Berleson, M., 1976, Acta Paediatr. Scand., 65: 279-287.

Further, studies of non-obese persons who deliberately attempted to gain weight by systematically over-eating found that some were more resistant to such weight gain than others and were able to maintain an elevated weight only by very high caloric intake. In contrast, spontaneously obese individuals are able to maintain their obese status with normal or only moderately elevated caloric intake.

In addition, it is a commonplace experience in animal husbandry that different strains of swine, cattle, etc., have different predispositions to obesity. Studies of the genetics of human obesity and of models of animal obesity demonstrate that obesity results from complex defective regulation of both food intake, food induced energy expenditure and of the balance between lipid and lean body anabolism.

There are a number of genetic diseases in man and other species, which feature obesity among their more prominent symptoms, along with, frequently, dysmorphic features and mental retardation. Although no mammalian gene associated with an obesity syndrome has yet been characterised in molecular terms, a number of such diseases exist in humans. For example, Prader-Willi syndrome (PWS) affects approximately 1 in 20,000 live births, and involves poor neonatal muscle tone, facial and genital deformities, and generally obesity. The genetics of PWS are very complex, involving, for example, genetic imprinting, in which development of the disease seems to depend upon which parent contributes the

abnormal PWS allele. In approximately half of all PWS patients, however, a deletion on the long arm of chromosome 11 is visible, making the imprinting aspect of the disease difficult to reconcile. Given the various symptoms generated, it seems likely that the PWS gene product may be required to normal brain function, and may, therefore, not be directly involved in adipose tissue metabolism.

In addition to PWS, many other pleiotropic syndromes, which include obesity as a symptom, have been characterised. These syndromes are more genetically straightforward, and appear to involve autosomal recessive alleles. The diseases, which include, among others, Ahlstrom, Carpenter, Bardet-Biedl, Cohen, and Morgagni-Stewart-Monel Syndromes. However, each of these is rare and they do not account for the human obesity epidemic.

There are a number of animal models with mutations that are associated with body weight and body composition disorders and attempts have been made to utilise such animals as models for the study of obesity. The best studied animal models for genetic obesity are mice, which contain the autosomal recessive mutations ob/ob (obese) or db/db (diabetes). These mutations are on chromosome 6 and four respectively, but lead to clinically similar pictures provided the genes are expressed on the same background strain. The ob gene product has been identified as 16kDa polypeptide produced primarily by adipose tissue that provides a signal to the brain on the adipose tissue fat stores. Mice with a mutation, resulting in no circulating protein (called leptin) are hyperphagic, obese, have poor thermo-regulation and non-shivering thermogenesis and are insulin resistant with

impaired glucose tolerance. Treatment of these mice with recombinant leptin reduces food intake and stimulates energy expenditure so that the mice become less obese.

10 Inbred mice have a mutation in the receptor for leptin so that normal signal transduction via the JAK/STAT pathway does not occur. This mutation, when on the C57BL/6 background, is phenotypically identical to the ob mutation, but causes additionally frank diabetes when on the C57BL/Ks background. Other single gene mutations in mice associated with obesity, include the yellow mutation at the agouti locus, mutations at the fat and tubby loci and an autosomal dominant mutation at the adipose locus on chromosome 7.

15 Other mutant animal models include fa/fa (fatty) rats and ZDF fatty rats, which bear strong respective similarities with the ob/ob and db/db mice. Thus the fa/fa rat is hyperphagic, obese, insulin resistant, very  
20 hyperinsulinaemic and glucose intolerant, whereas the ZDF rat is hyperphagic, obese, insulin resistant and hyperinsulinaemic, but develops frank diabetes after approximately 6 weeks of age.

25 Inbred mouse strains, such as the NZO mouse, the Japanese KK mouse are models of obesity. Further, desert rodents, such as spiny mice and sand rats are neither insulin resistant nor diabetic in their natural habitats, but do become insulin resistant and glucose intolerant when fed  
30 on a standard laboratory diet.

Obesity is a common feature of elderly rodents and the development of obesity can be accelerated by feeding diets with a high fat content, whether these diets are  
35 synthetic homogenous diets or are the result of

supplementation or replacement of the normal rat chow by human food with a high fat content (cafeteria diet).

5 In animal studies, it has been demonstrated that, as in humans, some animals are able to resist the obesity inducing effects of a diet with a high fat content. This resistance appears to be at, at least, two levels. First, there are differences in preferences for diet high in fat. Thus, some animals do not overeat when presented  
10 with a high fat diet, whereas others do. Secondly, animals show differences in their ability to resist obesity by activating energy wasting mechanisms.

15 All of these animal models have been used from time to time to evaluate new drugs that were potential treatments for body weight and eating disorders, including obesity. However, although individual changes in enzyme activities have been identified in some of the animal models and how this might be altered by a drug therapy, no systematic  
20 evaluation has been made of the differences in protein expression in the tissues of normal animals and the obese animals. It is these changes in protein expression that underlie the development of body weight and eating disorders, including obesity. It is the same changes in  
25 protein expression that are likely to be causative of obesity in humans and in companion animals such as dogs and cats. Given the severity and prevalence of obesity, there exists a great need for the systematic identification of the disease causing proteins, since  
30 modulation of the expression level of such proteins back to the level in non-obese state represents a means of treating the disease condition.

#### Summary of the Invention

35 Broadly, the present invention relates to methods and



completing or for the treatment of body weight and eating disorders, including but not limited to, obesity. More specifically, the present invention identifies and describes proteins that are differentially expressed in body weight and/or eating disordered states relative to their expression in normal, or non-body weight disordered states and also identifies proteins that are differentially expressed in response to manipulations relevant to body weight regulation and/or control of food intake. Such differentially expressed proteins may represent 'target proteins' and/or fingerprint proteins. Further, the present invention identifies and describes proteins termed pathway proteins via their ability to interact with proteins involved in the regulation of body weight and/or food intake. Pathway proteins may also exhibit target protein and/or fingerprint protein characteristics.

Accordingly, in the first aspect, the present invention provides a method of screening an agent to determine its usefulness in treating a condition characterised by body weight disorders and/or eating disorders, the method comprising:

(a) establishing a paradigm in which at least one protein is differentially expressed in relevant tissue from, or representative of, subjects have differential levels of obesity;

(b) obtaining a sample of relevant tissue taken from, or representative of, a subject have obesity, who or which has been treated with the agent being screened;

(c) determining the presence, absence or degree of expression of the differentially expressed protein or proteins in the tissue from, or representative of, the treated subject; and,

(d) selecting or rejecting the agent according to

the extent to which it changes the expression of the differentially expressed protein or proteins in the treated obese subject.

5 Typically, an agent is selected if it changes the expression of a differentially expressed protein towards that of a normal weight subject.

10 In a further aspect, the present invention provides a method for the identification of an agent or agents for use in the treatment of body weight and/or eating disorders comprising the steps of:

15 (a) identification of experimental and/or clinical paradigms that exhibit differential levels of obesity or lean or nutrient intake status (e.g. fed v fasted) or macronutrient selection (e.g. fat-preferring v non-fat preferring);

20 (b) identification of differentially expressed proteins in tissues of animals or humans exhibiting differential levels of obesity or leanness or nutrient intake states or macronutrient selection;

25 (c) selecting an agent that converts the expression of differentially expressed proteins in tissues of animals or humans exhibiting body weight or eating disorder dysfunctional states to that in the normal state for use in the treatment of the body weight or eating disordered state.

30 In a further aspect, the present invention provides the use of an agent identified by the above method for the preparation of a medicament for the treatment of a condition characterised by body weight or eating disorders. These conditions include obesity, non-insulin dependent diabetes (type 2 diabetes), Cushing syndrome,  
35 anorexia nervosa and bulimia.

In a further aspect, the present invention provides a method of treating a condition characterised by body weight or eating dysfunction in a patient, the method comprising administering a therapeutically or prophylactically effective amount of such an agent identified by the above method.

In a further aspect, the present invention provides a method of determining the nature or degree of body weight and/or eating dysfunction in a human or animal subject, the method comprising:

(a) establishing a paradigm in which at least one protein is differentially expressed in relevant tissue from, or representative of, subjects having a body weight and/or eating disorder;

(b) obtaining a sample of the tissue from the subject;

(c) determining the presence, absence or degree of expression of the differentially expressed protein or proteins in the sample; and

(d) relating the determination to the nature or degree of the body weight or eating disorder by reference to a previous correlation between such a determination and clinical information.

Conveniently, the patient sample used in method can be a tissue sample or body fluid sample or urine. This method allows the causes of body weight or eating disorder dysfunction of a patient to be correlated to different types to prophylactic or therapeutic treatment available in the art, thereby enhancing the likelihood of obtaining a beneficial response in the patient to the therapy.

In a further aspect, the present invention provides a method of treatment by the use of an agent that will

restore the expression of one or more differentially expressed proteins in the body weight or eating disorders dysfunction state to that found in the normal state in order to maintain a reduced body weight (prevent weight gain) or to prevent the re-emergence of an eating disorder.

In a further aspect, the present invention provides a method whereby the pattern of differentially expressed proteins in a tissue sample or body fluid sample or urine of an individual with body weight and/or eating disorder dysfunction is used to predict the most appropriate and effective therapy to alleviate the dysfunction state and to monitor the success of that treatment.

In a further aspect, the present invention provides a protein which is differentially expressed in relevant tissue from, or representative of subjects having differential levels of obesity or leanness or nutrient intake states or macronutrient selection and which is as obtainable by the method of two-dimensional gel electrophoresis carried out on said tissue or a protein-containing extract thereof, the method comprising:

(a) providing non-linear immobilised pH gradient (IPG) strips of acrylamide polymer 3mm x 180mm;

(b) rehydrating the IPG strips in a cassette containing 25ml of an aqueous solution of urea (8M), 3-[(cholamidopropyl)dimethylammonio]-1-propanesulphonate (CHAPS, 2% w/v), dithioerythritol (DTE, 10mM), mixture of acids and bases of pH 3.5 to 10 (2% w/v) and a trace of Bromophenol Blue;

(c) emptying the cassette of liquid, transferring the strips to an electrophoretic tray fitted with humid electrode wicks, electrodes and sample cups, covering the strips and cups with low viscosity paraffin oil;

(d) equilibrating the IPG strips in an aqueous solution of 0.5M, powdered material of the relevant dry tissue in urea 6M, THAPS 4% w/v, Tris 40 mM, DTE 65mM, SDS 1.0% w/v and a trace of Bromophenol Blue to the sample cups, at the cathode end of the IPG strips;

(e) carrying out isoelectric focusing on the gel at a voltage which increases linearly from 300 to 3500V during 3 hours, followed by another 3 hours at 3500V, and thereafter at 5000V for a time effective to enable the proteins to migrate in the strips to their pH-dependent final positions;

(f) equilibrating the strips within the tray with 100ml of an aqueous solution containing Tris-HCl (50mM) pH 6.8, urea (6M), glycerol (30% v/v), SDS (2% w/v) and DTE (2% w/v) for 12 minutes;

(g) replacing this solution by 100ml of an aqueous solution containing Tris-HCl (50mM) pH 6.8, urea (6M), glycerol (30% v/v), SDS (2% w/v), iodoacetamide (2.5% w/v) and a trace of Bromophenol Blue for 5 minutes;

(h) providing a vertical gradient slab gel 160 x 200 x 1.5mm of acrylamide/piperazine-diacrylyl cross-linker (9-16%T/2.6%C), polymerised in the presence of TEMED (0.5% w/v), ammonium persulphate (0.1% w/v) and sodium thiosulphate (5mM), in Tris-HCl (0.375M) pH 8.8 as leading buffer;

(i) over-layering the gel with sec-butanol for about 2 hours, removing the overlay and replacing it with water;

(j) cutting the IPG gel strips to a size suitable for the second dimensional electrophoresis, removing 6mm from the anode end and 14mm from the cathode end;

(k) over-laying the slab gel with an aqueous solution of agarose (0.5% w/v) and Tris-glycine-SDS (25mM-198mM - 0.1% w/v) as leading buffer, heated to 70°C and loading the IPG gel strips onto the slab gel through

this over-layered solution;

(l) running the second dimensional electrophoresis at a constant current of 40mA at 8-12°C for 5 hours; and, (m) washing the gel.

5

Examples of differentially expressed proteins are described in the examples below.

10 Alternatively, fingerprint proteins may be used in methods for identifying compounds useful for the treatment of body weight and/or eating disordered states. 'Target protein', as used herein, refers to a differentially expressed protein involved in body weight regulation and/or the control feeding such that  
15 modulation of the expression of that protein may act to prevent or ameliorate the body weight and/or eating disordered state including, but not limited to, obesity.

20 This invention is based, in part, on systematic search strategies involving modulations of body weight and/or eating behaviours and obesity experimental paradigms, coupled with sensitive detection of proteins by 2D-electrophoresis.

25 The invention further provides methods for the identification of compounds that modulate the expression of proteins involved in body weight and feeding processes relevant to the regulation of energy balance. Still further, the present invention describes methods for the  
30 prevention and/or treatment of obesity, which may involve the administration of such compounds to individuals predisposed to or exhibiting obesity.

35 Additionally, the present invention describes methods for the prognostic and diagnostic evaluation of subjects with

body weight and eating disordered states in order to make a prognosis of the most effective therapy for each subject.

The examples presented below illustrate the successful use of the experimental paradigms of the invention to identify target proteins associated with a body weight and or eating disordered state.

### Definitions

"Differential expression", as used herein, refers to at least one recognisable difference in tissue protein expression. It may be a quantitatively measurable, semi-quantitatively estimatable or qualitatively detectable difference in tissue protein expression. Thus, a differentially expressed protein (herein DEP) may be strongly expressed in tissue in the normal state and less strongly expressed or not expressed at all in tissue in the body weight or eating disordered state. Conversely, it may be strongly expressed in tissue in the disorder state but less strongly expressed or not expressed at all in the normal state. Similarly the differential expression can be either way around in the comparison between untreated and treated tissue. Further, expression may be regarded as differential if the protein undergoes any recognisable change between the two states under comparison.

Thus, in contrast to prior art methods as described in US Patent No:5,702,902 which identify differentially expressed genes by examining RNA, mRNA or cDNA libraries derived from different tissue types, the present invention is based on methods which directly determine differentially expressed proteins present in tissue samples, by employing techniques such as 2D gel

electrophoresis.

The term "paradigm" means a prototype example, test model or standard.

5

Wherever a differentially expressible protein is used in the screening procedure, it follows that there must have been at some time in the past a preliminary step of establishing a paradigm by which the differential  
10 expressibility of the protein was pre-determined. Once the paradigm has been established, it need not be re-established on every occasion that a screening procedure is carried out. The term "establishing a paradigm" is to be construed accordingly.

15

Body weight and/or eating disordered state includes conditions in which the body mass is either below normal or above normal and conditions in which eating behaviour is abnormal. Conditions characterised by body weight  
20 and/or eating disordered state include obesity, anorexia, bulimia and cathexic states associated with cancer, AIDS and trauma.

25

Nutrient intake status includes any paradigm providing a difference in nutrient intake such as differences between fed and fasting, over-feeding v normal feeding, meal eating v ad-libitum eating, sated v unsated.

30

Macronutrient selection includes paradigms in which individuals or animals select or are provided different macronutrients such as high fat v low fat, fat preferring v carbohydrate preferring.

35

"Relevant tissue" means any tissue which undergoes a biological change in the body weight or eating disordered



state of the experimental paradigm.

"Tissue representative of subjects" means any tissue in which the above-mentioned biological change can be simulated for laboratory purposes and includes, for example, a primary cell culture or cell line derived ultimately from relevant tissue.

The term "subjects" includes human and animal subjects.

The treatments referred to above can comprise the administration of one or more drugs or foodstuffs, and/or other factors such as diet or exercise.

The differentially expressed proteins (DEPs) include "fingerprint proteins", "target proteins" or "pathway proteins".

The term "fingerprint protein", as used herein, means a DEP, the expression of which can be used, alone or together with other DEPs, to monitor or assess the condition of a patient suspected of suffering from a bodyweight or eating disordered state. Since these proteins will normally be used in combination, especially a combination of four or more, they are conveniently termed "fingerprint proteins", without prejudice to the possibility that on occasions they may be used singly or along with only one or two other proteins for this purpose. Such a fingerprint protein or proteins can be used, for example, to diagnose a particular type of body weight or eating disorder and thence to suggest a specific treatment for it.

The term "diagnosis", as used herein, includes the provision of any information concerning the existence,

non-existence or probability of the disorder in a patient. It further includes the provision of information concerning the type or classification of the disorder or of symptoms, which are or may be experienced in connection with it. It encompasses prognosis of the medical course of the disorder.

The term "target protein", as used herein, means a DEP, the level or activity of which can be modulated by treatment to alleviate a body weight or eating disordered state. Modulation of the level or activity of the target protein in a patient may be achieved, for example, by administering the target protein, another protein or gene which interacts with it, or an agent which counteracts or reduces it, for example an antibody to the protein, competitive inhibitor of the protein or an agent which acts in the process of transcription or translation of the corresponding gene.

Alternatively or additionally, the DEPs can interact with at least one other protein or which a gene involved in the regulation of body weight or eating. Such other proteins are termed herein "pathway proteins" (PPs). The term is applied to the protein with which it, the DEP, interacts, not the DEP itself, although a pathway protein can be another DEP.

By way of example, embodiments of the present invention will now be described in more detail with reference to the accompanying figures.

#### Brief Description of the Figures

Figures 1A-E show computer images of stained 2-DGE gels from the liver tissue of lean mice identifying spots thereon, including DEPs.

Figures 1-7 show DEPs which are underexpressed in ob/ob mouse liver tissue relative to expression in lean mouse liver tissue.

Figures 8-11 show DEPs which are underexpressed in ob/ob mouse skeletal muscle relative to expression in lean mouse skeletal muscle, and DEPs which are overexpressed in ob/ob skeletal muscle relative to lean mouse skeletal muscle.

Figures 12-23 show DEPs which are underexpressed in ob/ob mouse adipose tissue relative to lean mouse adipose tissue, and DEPs which are overexpressed in obese mouse adipose tissue relative to adipose tissue of lean mice.

Figures 24-29 show DEPs which are underexpressed in ob/ob mouse brown adipose tissue relative to lean mouse brown adipose tissue, and DEPs which are overexpressed in obese mouse brown adipose tissue relative to brown adipose tissue of lean mice.

#### Detailed Description

Methods and compositions for the treatment of body weight and/or eating disordered states including, but not limited to, obesity. Proteins termed 'target proteins' and/or fingerprint proteins are described which are differentially expressed in body weight and/or eating disordered states relative to their expression in normal states and/or which are differentially expressed in response to manipulations relevant to the regulation of body weight and/or eating. Additionally, proteins termed 'pathway proteins' are described which interact with proteins involved in regulation of body weight and/or eating. Methods for the identification of such fingerprint target and pathway proteins are also

described.

Described below are methods for the identification of compounds, which modulate the expression of proteins, involved in the regulation of body weight and/or eating. Additionally described below are methods for the treatment of body weight and/or eating disordered states including, but not limited to, obesity.

Also discussed below are methods for prognostic and diagnostic evaluation of body weight and/or eating disordered states and for the identification of subjects exhibiting a predisposition to such disorders and for identifying the most appropriate therapy for such individuals.

#### 1. Identification of differentially expressed and pathway proteins

In one embodiment, the present invention concerns methods for the identification of proteins which are involved in: body weight and/or eating disorders and/or which are involved in obesity. Such proteins may represent proteins, which are differentially expressed in body weight and/or eating disordered states relative to their expression in normal states. Further, such proteins may represent proteins that are differentially expressed or regulated in response to manipulation relevant to modulating body weight and/or food intake. Such differentially expressed proteins may represent 'target' or 'fingerprint' proteins. Methods for the identification of such proteins are described in section 1.1. Methods for the further characterisation of such differentially expressed proteins and for their identification as target and/or fingerprint proteins are presented below in section 1.3.

10  
In addition, data on the expression of proteins in section 1.2, for the identification of proteins termed pathway proteins involved in body weight and in eating disordered states and in obesity. Pathway proteins, as used herein, refer to a protein, which exhibits the ability to interact with other proteins relevant to body weight and in eating disordered states. A pathway protein may be differentially expressed and therefore may have the characteristics of a target or fingerprint protein.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213  
2214  
2215  
2216  
2217  
2218  
2219  
2220  
2221  
2222  
2223  
2224  
2225  
2226  
2227  
2228

differs in normal versus body weight and/or eating  
disordered states or control versus experimental states  
need only be large enough to be visualised via standard  
characterisation techniques, such as silver staining of  
SD-electrophoretic gels. Other such standard  
characterisation techniques by which expression  
differences may be visualised are well known to those  
skilled in the art. These include successive  
chromatographic separations of fractions and comparisons  
of the peaks, capillary electrophoresis and separations  
using micro-channel networks, including on a microchip.

Chromatographic separations can be carried out by high  
performance liquid chromatography as described in  
Pharmacia literature, the chromatogram being obtained in  
the form of a plot of absorbance of light at 280nm  
against time of separation. The material giving  
incompletely resolved peaks is then re-chromatographed  
and so on.

Capillary electrophoresis is a technique described in  
many publications, for example in the literature "Total  
CE Solutions" supplied by Beckman with their P/ACE 5000  
system. The technique depends on applying an electric  
potential across the sample contained in a small  
capillary tube. The tube has a charged surface, such as  
negatively charged silicate glass. Oppositely charged  
ions (in this instance, positive ions) are attracted to  
the surface and then migrate to the appropriate electrode  
of the same polarity as the surface (in this instance,  
the cathode). In this electro-osmotic flow (EOF) of the  
sample, the positive ions move fastest, followed by  
uncharged material and negatively charged ions. Thus,  
proteins are separated essentially according to charge on  
them.

Micro-channel networks function somewhat like capillaries and can be formed by photolithiation of a polymeric material. In this technique, a UV laser is used to generate high energy light pulses that are fired in a series of polymer having suitable UV absorption characteristics, for example polyethylene terephthalate or polycarbonate. The incident photons break chemical bonds with a confined space, leading to a rise in internal pressure, mini-explosions and ejection of the ablated material, leaving behind voids which form micro-channels. The micro-channel material achieves a separation based on EOF, as for capillary electrophoresis. It is adaptable to micro-chip form, each chip having its own sample injector, separation column and electrochemical detector: see J.S. Rossier et al, 1999, Electrophoresis 20: pp. 727-731.

Differentially expressed proteins may be further described as target proteins and/or fingerprint proteins. 'Fingerprint proteins', as used herein, refer to a differentially expressed protein whose expression pattern may be utilised as part of a prognostic or diagnostic body weight and/or eating disorder evaluation or which, alternatively, may be used in methods for identifying compounds useful for the treatment of body weight and/or eating disordered states. A fingerprint protein may also have characteristics of a target protein or a pathway protein.

'Target protein', as used herein, refers to a differentially expressed protein involved in body weight and/or eating disordered states and/or obesity such that modulation of the level or activity of the protein may act to prevent the development of the disordered states including, but not limited to, obesity. A target protein

may also have the characteristics of a fingerprint protein or a pathway protein.

### 1.1 Method for the identification of differentially expressed proteins

A variety of methods may be used for the identification of proteins, which are involved in body weight and/or eating disordered states and/or which may be involved in obesity. Described in Section 1.1.1 are several experimental paradigms, which may be utilised for the generation of subjects, and samples, which may be used for the identification of such proteins. Material from the paradigm control and experimental subjects may be characterised for the presence of differentially expressed protein sequences as discussed below in Section 1.1.2.

#### 1.1.1 Paradigms for the identification of differentially expressed proteins

Among the paradigms that may be utilised for the identification of differentially expressed proteins involved in body weight and/or obesity disordered states are paradigms designed to analyse those proteins that are differentially expressed between normal and body weight and/or eating disordered states including, but not limited to, obesity.

In one embodiment of such a paradigm tissue from normal and body weight and/or eating disorder subjects would be compared. Such subjects could include, but would not be limited to, subjects with obesity. It could also involve a comparison of normal subjects and subjects who have resisted the development of obesity despite overfeeding. Appropriate tissues would include, but not be limited to, blood and adipose tissue. It could also include post-



artery samples from subjects. Particularly useful tissues would include brain particularly the hypothalamus, skeletal muscle, liver and adipose tissue.

Among additional paradigms would include a comparison of obese subjects and obese subjects whose body weight had been reduced by, but not limited to, dietary restriction or dietary modification, anorexic drugs such as sibutramine, 5HT receptor antagonists, leptin and leptin mimetics, MC4 agonists, exercise and thermogenic drugs such as  $\beta_3$ -adrenoceptor agonists.

In a further paradigm, which may be utilised for the identification of differentially expressed proteins involved in body weight and/or eating disorders are paradigms designed to analyse those proteins which may be involved in genetic models of obesity. Accordingly, such paradigms are referred to as 'genetic obesity paradigms'.

In the case of mice, for example, such paradigms may identify the proteins regulated either directly or indirectly by the *ob*/*ob*, *db*/*db*, *tub* or *fat* gene products. In rats such a paradigm may identify proteins regulated either directly or indirectly by the *fa* gene product.

In one embodiment of such a paradigm, test subjects may include *ob*/*ob*, *db*/*db*, *tub*/*tub* or *fat*/*fat* experimental mice and lean littermate controls. Test subjects could also include *fa*/*fa* and male and female ZDF rats. Samples of tissues such as skeletal muscle, whole brain, hypothalamus, adipose tissue and liver would be obtained. The examples below demonstrate the use of such genetic paradigms in identifying proteins which are differentially expressed in obese animals versus normal animals.

In additional embodiments, ob/ob, db/db, tub/tub and/or fat/fat mice and/or fa/fa and ZDF rats and lean control animals and inbred or outbred strains of rodents may be treated with drugs that reduce body weight, particularly body fat mass. Such drugs include, but are not limited to, appetite suppressants such as sibutramine, fenfluramine, NPY antagonists, melanocortin-4 receptor agonists, orexin antagonists, MCH antagonists, thermogenic drugs such as  $\beta_3$ -adrenoceptor agonists and anti-obesity agents such as leptin, leptin mimetics and other cytokines such as axokine. Such a paradigm allows the identification of target proteins.

In a further additional embodiment, ob/ob, db/db, tub/tub and/or fat/fat mice and/or fa/fa and/or ZDF rats and lean controls or inbred or outbred strains of rodents may be offered dietary treatments to either worsen the obese state or reduce the level of obesity or to identify animals that resist dietary obesity. For example, either lean or obese animals could be provided with a high fat diet to exacerbate the obese state.

In one embodiment of such a paradigm, Sprague Dawley rats would be fed on a high fat diet or a cafeteria diet consisting of human snack foods. Some of the rats become obese whilst others resist obesity. Thus, this paradigm can be used to select proteins that are associated with a predisposition to the development of obesity and to proteins associated with an ability to resist dietary obesity. This paradigm can be further refined by incorporating drug treatment or exercise paradigms.

In another embodiment of this paradigm, obese rodents that had been weight reduced by dietary restriction would be allowed access to ad-libitum food whilst a control

group of obese rodents would remain dietary restricted. Such a paradigm would allow the identification of proteins associated with the regain of obesity following withdrawal of dietary restriction.

Some native animal strains do not exhibit obesity in the wild but do when fed a laboratory chow or other laboratory diets. These include the desert rodents, the spiny mouse and the sand rat. Comparison of animals fed on the natural diet and those fed on a laboratory diet allows identification of proteins associated with body weight disorders and obesity.

A particularly important tissue with respect to the control of feeding behaviour and the regulation of energy balance is the hypothalamus. It is clear that many substances act in this area of the brain to regulate feeding and/or energy balance. These include catecholamines, serotonergic agents, leptin, orexins, melanocyte concentrating hormone, melanocortin receptor agonists and antagonists. It is also clear that there are complex interactions between these various substances.

However, no systematic evaluation of the changes in protein composition of the hypothalamus and its constituent nuclei, which underlay the changes in feeding behaviour, has yet been undertaken. Thus, in a further embodiment, hypothalamic nuclei from fed v fasted rodents; sated v non-sated rodents; obese v lean rodents; fat preferring v non-fat preferring rodents may be used to identify the hypothalamic protein patterns associated with particular feeding behaviours.

In addition to whole animal studies, paradigms include

systems in which isolated cells such as adipocytes, are incubated in vitro with agents such as leptin.

#### 1.1.2 Analysis of paradigm material

In order to identify differentially expressed proteins, tissues from subjects utilised in paradigms such as those described above in 1.1.1 are obtained. In addition, blood and body fluids may be analysed since the differentially expressed proteins might be released into the circulations.

Whole tissue or isolated cells may be used. Sub-cellular fractions of cells might also be used. Particularly useful sub-cellular fractions include the nuclear protein fraction.

#### 1.2 Methods for the identification of pathway proteins

Methods are described herein for the identification of pathway proteins. 'Pathway protein', as used herein, refers to a protein which exhibits the ability to interact with differentially expressed proteins involved in body weight and/or eating disorders and/or to interact with differentially expressed proteins which are relevant to obesity. A pathway protein may be differentially expressed and, therefore, may have the characteristics of a target and/or fingerprint protein.

Any method suitable for detecting protein-protein interactions may be employed for identifying pathway proteins by identifying interactions between proteins and proteins known to be differentially expressed in body weight and/or eating disordered states and/or obesity regulation. Such differentially expressed proteins may be cellular or extracellular proteins. Those proteins, which interact with such differentially expressed

proteins, represent pathway gene products.

Among the traditional methods, which may be employed, are co-immunoprecipitation, crosslinking and size exclusion through gradients or chromatographic columns. Utilising these methods such as those allow for the identification of pathway proteins. Once identified, a pathway protein may be used, in conjunction with standard techniques, to identify its corresponding pathway gene. For example, at least a portion of the amino acid sequence of the pathway gene product may be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique (see, e.g. Creighton (1983, 'Proteins: Structures and Molecular Principles', W.H. Freeman & Co., N.Y., pp. 34-49). The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for pathway gene sequences. Screening may be accomplished, for example, by standard hybridisation or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known (see, e.g. Ausubel, supra. and PCR Protocols: A Guide to Methods and Applications (1990) Innis, M. et al., eds. Academic Press Inc., New York).

One method, which detects protein interactions in vivo, the two-hybrid system, is described in detail for illustration only and not by way of limitation. One version of this system has been described (Chien et al (1991) Proc. Natl. Acad. Sci. USA, 88, 9578-9592) and is commercially available from Clontech (Palo Alto, Calif.).

Briefly, utilising such a system, plasmids are constructed that encode two hybrid proteins: one consists of the DNA-binding domain of a transcription

activator protein fused to a known protein, in this case, the differentially expressed protein known to be involved in body weight and/or eating disordered states and/or obesity regulation, and the other consists of the transcription activator protein's activation domain fused to an unknown protein that is encoded by a cDNA which has been recombined into this plasmid as part of a cDNA library. The plasmids are transformed into a strain of the yeast *Saccharomyces cerevisiae* that contains a reporter gene (e.g. *lacZ*) whose regulatory region contains the transcription activator's binding sites. Either hybrid protein alone cannot activate transcription of the reporter gene: the DNA-binding domain hybrid cannot because it does not provide activation function and the activation domain hybrid cannot because it cannot localise to the activator's binding sites. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

The two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with a known differentially expressed 'bait' protein. Total genomic or cDNA sequences are fused to the DNA encoding an activation domain. This library and a plasmid encoding a hybrid of the bait protein product fused to the DNA-binding domain are co-transformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene. For example, and not by way of limitation, the bait gene can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein. These colonies are purified and the library plasmids responsible for reporter gene

expression are isolated. RNA sequencing is then used to identify the proteins encoded by the library plasmids.

A cDNA library of the cell line from which proteins that interact with bait proteins are to be detected can be made using methods routinely practised in the art. According to the particular system described herein, for example, the cDNA fragments can be inserted into a vector such that they are translationally fused to the activation domain of GAL4. This library can be co-transformed along with the bait-gene GAL4 fusion plasmid into a yeast strain, which contains a lacZ gene driven by a promoter which contains GAL4 activation sequence. A cDNA encoded protein, fused to GAL4 activation domain, that interacts with bait gene product will reconstitute an active GAL4 protein and thereby drive expression of the lacZ gene. Colonies which express lacZ can be detected by their blue color in the presence of X-gal. The cDNA can then be purified from these strains, and used to produce and isolate the bait gene-interacting protein using techniques routinely practised in the art.

Once a pathway protein has been identified and isolated, it may be further characterised as, for example, discussed below, in Section 1.3.

### 1.3 Characterisation of differentially expressed and pathway proteins

Differentially expressed proteins, such as those identified via the methods discussed, above, in Section 1.1, and pathway genes, such as those identified via the methods discussed, above, in Section 1.2, above, as well as genes identified by alternative means, may be further characterised by utilising, for example, methods such as those discussed herein. Such proteins will be referred

to herein as 'identified proteins'.

Analyses such as those described herein, yield information regarding the biological function of the identified proteins. An assessment of the biological function of the differentially expressed proteins, in addition, will allow for their designation as target and/or fingerprint proteins.

Specifically, any of the differentially expressed proteins whose further characterisation indicates that a modulation of the proteins expressed or a modulation of the proteins activity may ameliorate any of the body weight and/or eating disorders will be designated 'target proteins', as defined above, in Section 1. Such target proteins, along with those discussed below, will constitute the focus of the compound discovery strategies discussed below, in Section 3. Further, such target proteins and/or modulating compounds can be used as part of the treatment and/or prevention of body weight and/or eating disorders and/or obesity.

Any of the differentially expressed proteins whose further characterisation indicates that such modulations may not positively affect body weight and/or eating disorders, but whose expression pattern contributes to a protein 'fingerprint' pattern correlative of, for example, a body weight and/or eating disordered state, will be designated a 'fingerprint protein'. 'Fingerprint patterns' will be more fully discussed below, in Section 7.1. It should be noted that each of the target proteins may also function as fingerprint proteins, as well as may all or a portion of the pathway proteins.

It should further be noted that the pathway proteins may



will be characterised using the techniques such as those described herein. These pathway proteins which yield information indicating that they are differentially expressed and that modulation of the proteins expression or modulation of the protein expression or modulation of the proteins activity may ameliorate any of the body weight and/or eating disorders of interest will also be designated 'target proteins'. Such target proteins, along with those discussed above, will constitute the focus of the compound discovery strategies discussed below, in Section 3 and can be used as part of the treatment methods described in Section 4, below.

It should be additionally noted that the characterisation of one or more of the pathway proteins may reveal a lack of differential expression, but evidence that modulation of the gene's activity or expression may, nonetheless, ameliorate body weight and/or eating disorder symptoms. In such cases, these genes and gene products would also be considered a focus of the compound discovery strategies of Section 3 below.

In instances wherein a pathway proteins characterisation indicates that modulation of gene expression or gene product activity may not positively affect body weight and/or eating disorders of interest, but whose expression is differentially expressed and contributes to a gene expression fingerprint pattern correlative of, for example, a body weight and/or eating disordered state, such pathway genes may additionally be designated as fingerprint genes.

A variety of techniques can be utilised to further characterise the identified proteins. First, the corresponding nucleotide sequence of the identified

protein may be obtained by utilising standard techniques well known to those of skill in the art, may, for example, be used to reveal homologies to one or more known sequence motifs which may yield information regarding the biological function of the identified protein.

Secondly, the biological function of the identified proteins may be more directly assessed by utilising relevant in vivo and in vitro systems. In vivo systems may include, but are not limited to, animal systems, which naturally exhibit body weight and/or eating disorder-like symptoms, or ones which have been engineered to exhibit such symptoms. Further, such systems may include systems for the further characterisation of body weight and/or eating disorders, and/or obesity, and may include, but are not limited to, naturally occurring and transgenic animal systems such as those described above, in Section 1.1.1, and Section 2.2.1 below. In vitro systems may include, but are not limited to, cell-based systems comprising cell types known to be associated with energy storage and metabolism. Such cells may be wild type cells, or may be non-wild type cells containing modifications known to, or suspected of, contributing to a body weight and/or eating disorder of interest. Such systems are discussed in detail below, in Section 2.2.2.

In further characterising the biological function of the identified proteins, the expression of these proteins may be modulated within the in vivo and/or in vitro systems, i.e. either overexpressed or underexpressed in, for example, transgenic animals and/or cell lines, and its subsequent effect on the system then assayed. Alternatively, the activity of the identified protein may

may be regulated by either increasing or decreasing the level of activity in the in vitro and/or in vivo system of interest, and its subsequent effect then assayed.

The information obtained through such characterisations may suggest relevant methods for the treatment of body weight and/or eating disorders involving the protein of interest. Further, relevant methods for the control of obesity involving the protein of interest may be suggested by information obtained from such characterisations. For example, treatment may include a modulation of protein expression and/or protein activity. Characterisation procedures such as those described herein may indicate where such modulation should involve an increase or a decrease in the expression or activity of the protein of interest. Such methods of treatment are discussed below, in Section 4.

## **2. Differentially expressed and pathway proteins**

Identified proteins, which include, but are not limited to, differentially expressed proteins such as those identified in Section 1.1 above, and pathway proteins, such as those identified in Section 1.2 above, are described herein. Specifically, the amino acid sequences of such identified proteins are described. Further, antibodies directed against the identified protein, and cell- and animal-based models by which the identified proteins may be further characterised and utilised are also discussed in this Section.

### **2.1 Antibodies specific for differentially expressed or pathway proteins**

Described herein are methods for the production of antibodies capable of specifically recognising one or more differentially expressed or pathway protein.

epitopes. Such antibodies may include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs), humanised or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')<sub>2</sub> fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Such antibodies may be utilised as part of body weight and/or eating disorder treatment methods, and/or may be used as part of diagnostic techniques whereby patients may be tested for abnormal levels of fingerprint, target, or pathway gene proteins, or for the presence of abnormal forms of such proteins.

For the production of antibodies to a differentially expressed or pathway protein, various host animals may be immunised by injection with a differentially expressed or pathway protein, or a portion thereof. Such host animals may include, but are not limited to, rabbits, mice and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvant such as BCG bacille Calmette-Fuerin) and *Corynebacterium parvum*.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunised with an antigen, such as target proteins, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be immunised by injection with differentially expressed or pathway protein supplemented with adjuvants as also described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique, which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein (1975, Nature 258: 451-456; and US Pat. No. 4,374,111), the human x-cell hybridoma technique (Gresser, et al., 1983, Immunology Today 4: 71; Cole, et al., 1983, Proc. Natl. Acad. Sci. USA 80: 2034-2038), and the EBV-hybridoma technique (Cole, et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan F. Liss Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

In addition, techniques developed for the production of 'chimeric antibodies' (Morrison, et al., 1984, Proc. Natl. Acad. Sci. 81: 6851-6855; Neuberger, et al., 1984, Nature 312: 604-608; Takeda, et al., 1985, Nature 314: 452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

Alternatively, techniques described for the production of single chain antibodies (US Pat. No. 4,946,778; Bird, 1986, Science 242: 423-426; Huston, et al., 1986, Proc.

Natl. Acad. Sci. USA 86: 5979-5983; and Ward, et al., 1989, Nature 334: 544-546) can be adapted to produce differentially expressed or pathway protein-single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments, which recognise specific epitopes, may be generated by known techniques. For example, such fragments include, but are not limited to, the F(ab'); fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab'); fragments. Alternative, Fab expression libraries may be constructed (Huse, et al., 1989, Science 246: 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

## 2.2 Cell- and animal-based model systems

Described herein are cell- and animal-based systems, which act as models for body weight and or eating disorders. These systems may be used in a variety of applications. For example, the animal-based model systems can be utilised to identify differentially expressed proteins via one of the paradigms described above, in Section 1.1.1. Cell- and animal-based model systems may be used to further characterise differentially expressed and pathway proteins, as described above in Section 1.3. Such further characterisation may, for example, indicate that a differentially expressed protein is a target protein. Second, such assays may be utilised as part of screening strategies designed to identify compounds which are capable of ameliorating body weight and/or eating

disorder symptoms, as described below. Thus, the animal- and cell-based models may be used to identify drugs, pharmaceuticals, therapies and interventions which may be effective in treating such body weight and/or eating disorders. In addition, as described in detail below, in Section 6, such animal models may be used to determine the LD<sub>50</sub> and the ED<sub>50</sub> in animal subjects, and such data can be used to determine the in vivo efficacy of potential body weight and/or eating disorder treatments, including treatments for obesity.

#### 2.2.1 Animal-based systems

Animal-based model systems of body weight and/or eating disorders may include, but are not limited to, non-recombinant and engineered transgenic animals.

Non-recombinant animal models for body weight and/or eating disorders may include, for example, genetic models. Such genetic body weight and/or eating disorder models may include, for example, mouse models of obesity such as mice homozygous for the autosomal recessive ob, db, fat or tub alleles. It could also include rat models, for example fa/fa rats.

Non-recombinant, non-genetic animal models of body weight and/or eating disorder may include, for example, rats or mice fed on a diet containing a large amount of fat. Such diets could be synthetic diets in which the fat content (by calorific value) is more than 50%.

Alternative human foods with a high fat content, such as salami and butter, may be provided to the animals.

Additionally, animal models exhibiting body weight and/or eating disorder-like symptoms may be engineered by utilising, for example, the gene sequences of target

proteins such as those described above, in Section 2, in conjunction with techniques for producing transgenic animals that are well known to those of skill in the art. For example, gene sequences of target proteins may be introduced into, and overexpressed in, the genome of the animal of interest, or, if endogenous gene sequences of target proteins are present, they may either be overexpressed or, alternatively, may be disrupted in order to underexpress or inactivate gene expression of target proteins.

In order to overexpress the target gene sequence of a target protein, the coding portion of the target gene sequence may be ligated to a regulatory sequence, which is capable of driving gene expression in the animal and cell type of interest. Such regulatory regions will be well known to those of skill in the art, and may be utilised in the absence of undue experimentation.

For underexpression of an endogenous gene sequence of a target protein, such a sequence may be isolated and engineered such that when reintroduced into the genome of the animal of interest, the endogenous gene alleles of the target protein will be inactivated. Preferably, the engineered gene sequence of the target protein is introduced via gene targeting such that the endogenous sequence is disrupted upon integration of the engineered target gene sequence into the animal's genome.

Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, mini-pigs, goats and non-human primates, e.g. baboons, squirrel, monkeys, rhesus monkeys and chimpanzees may be used to generate body weight and/or eating disorder animal models.



Any technique known in the art may be used to introduce a target gene transgene or a target protein into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Hoppe, I.J. and Wagner, I.E., 1988, US Pat. No. 4,873,161 ; retrovirus mediated gene transfer into germ lines (Van der Putter et al., 1988, Proc. Natl. Acad. Sci., USA 85: 6149-6152 ; gene targeting in embryonic stem cells (Thompson et al., 1989, Cell 56: 313-321 ; electroporation of embryos (Lo, 1988, Mol. Cell Biol. 8: 1803-1814 ; and sperm-mediated gene transfer (Lavitrand et al., 1989, Cell 57: 717-723); etc. For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 118: 171-229.

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e. mosaic animals (see, for example, techniques described by Jakobovits, 1994, Curr. Biol. 4: 761-763). The transgene may be integrated as a single transgene or in concatamers, e.g. head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko, M. et al., 1992, Proc. Natl. Acad. Sci. USA 89: 6232-6236). The regulatory sequences required to such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

When it is desired that the target gene transgene be integrated into the chromosomal site of the endogenous target gene, gene targeting is preferred. Briefly, when such a technique is to be utilised, vectors containing

some nucleotide sequences homologous to the gene of the endogenous target protein of interest are designed for the purpose of integrating, via homologous recombination, with chromosomal sequences, into and disrupting the function of, the nucleotide sequence of the endogenous target gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene of interest in only that cell type, by following, for example, the teaching of Gu et al. (Gu, H. et al., 1994, Science 265: 103-106). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant target gene and protein may be assayed utilising standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyse animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, in situ hybridisation analysis, and RT-PCR. Samples of target protein-expressing tissue may also be evaluated immunocytochemically using antibodies specific for the transgene protein of interest.

The target protein transgenic animals that express target gene mRNA or target protein transgene peptide (detected immunocytochemically, using antibodies directed against target protein epitopes) at easily detectable levels should then be further evaluated to identify those

animals which display characteristics of body weight and/or eating disorder-like symptoms. Such symptoms may include, for example, obesity, hyperphagia, hypophagia, leanness, altered intolerance, hyperinsulinaemia, and insulin-dependent diabetes. Additionally, specific cell types within the transgenic animals may be analysed and assayed for cellular phenotypes characteristic of body weight and/or eating disorders. Further, such cellular phenotypes may include an assessment of a particular cell types fingerprint pattern of expression and its comparison to known fingerprint expression profiles of the particular cell type in animals exhibiting body weight and/or eating disorders. Such transgenic animals serve as suitable model systems for body weight and/or eating disorders.

Once target protein transgenic founder animals are produced (i.e. those animals which express target proteins in cells or tissues of interest and which, preferably, exhibit symptoms of body weight and/or eating disorders), they may be bred, inbred, outbred or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to, outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound target protein transgenics that transgenically express the target protein of interest at higher levels because of the effects of additive expression of each target gene transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the possible need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or

homozygous lines; breeding animals to different inbred genetic backgrounds so as to examine effects of modifying alleles on expression of the target protein and the development of body weight and/or eating disorder-like symptoms. One such approach is to cross the target protein transgenic founder animals with a wild type strain to produce an F1 generation that exhibits body weight and/or eating disorder-like symptoms, such as hyperphagia, hypophagia, obesity and leanness. The F1 generation may then be inbred in order to develop a homozygous line, if it is found that homozygous target protein transgenic animals are viable.

#### 2.2.2 Cell-based assays

Cells that contain and express target gene sequences which encode target proteins and, further, exhibit cellular phenotypes associated with an obesity disorder, may be utilised to identify compounds that exhibit an ability to ameliorate body weight and/or eating disorder symptoms. Cellular phenotypes, which may indicate an ability to ameliorate body weight and/or eating disorders, may include, for example, resistance to insulin.

Further, cell lines which may be used for such assays may also include recombinant, transgenic cell lines. For example, the body weight and/or eating disorder animal models of the invention discussed above, in Section 2.2.1, may be used to generate cell lines, containing one or more cell types involved in body weight and/or eating disorders, that can be used as cell culture models for this disorder. While primary cultures derived from the body weight and/or eating disorder transgenic animals of the invention may be utilised, the generation of continuous cell lines is preferred. For examples of

transgenic animals, which may be used to derive a continuous cell line from the transgenic animals, see Small, et al., 1988, Mol. Cell Biol. 8: 642-648.

Alternatively, cell lines have been shown to be involved in many weight and/or eating disorders may be transfected with sequences capable of increasing or decreasing the amount of target protein within the cell. For example, gene sequences of target proteins may be introduced into, and overexpressed in, the genome of the cell of interest, or, if endogenous gene sequences of the target protein are present, they may either be overexpressed or, alternatively, be disrupted in order to underexpress or inactivate target protein expression.

In order to overexpress a gene sequence of a target protein, the coding portion of the target gene sequence may be ligated to a regulatory sequence, which is capable of driving gene expression in the cell type of interest. Such regulatory regions will be well known to those of skill in the art, and may be utilised in the absence of undue experimentation.

For underexpression of an endogenous target protein the gene sequence may be isolated and engineered such that when reintroduced into the genome of the cell type of interest, the endogenous target gene alleles will be inactivated. Preferably, the engineered target gene sequence is introduced via gene targeting such that the endogenous target sequence is disrupted upon integration of the engineered target gene sequence into the cell's genome. Gene targeting is discussed above, in Section 2.2.1.

Transfection of target protein gene sequence nucleic acid

may be accomplished by utilizing standard techniques. See, for example, Ausubel, 1988, supra. Transfected cells should be evaluated for the presence of the recombinant target gene sequences, for expression and accumulation of target gene mRNA, and for the presence of recombinant target protein production. In instances wherein a decrease in target protein expression is desired, standard techniques may be used to demonstrate whether a decrease in endogenous target gene expression and/or in target protein production is achieved.

### 3. Screening assays for compounds that interact with the target proteins

The following assays are designed to identify compounds that bind to target proteins, bind to other cellular proteins that interact with a target proteins, and to compounds that interfere with the interaction of the target proteins with other cellular proteins. Such compounds may include, but are not limited to, other cellular proteins. Methods for the identification of such cellular proteins are described below, in Section 3.2

Compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including, but not limited to, Ig-tailed fusion peptides, comprising extracellular portions of target protein transmembrane receptors, and members of random peptide libraries (see, e.g. Lam, K.S. et al., 1991, Nature 354: 82-84; Houghten, R. et al., 1991, Nature 354: 84-86; made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, member of random or partially degenerate, directed phosphopeptide libraries: see, e.g., Songyang, Z. et al., 1993, Cell 72: 767-778), antibodies (including, but not limited to, polyclonal,

proteins, nucleic acids, carbohydrates, lipids, and small organic molecules, and DNA, RNA, and PNA expression. Library fragments, and epitope-binding fragments thereof and small organic or inorganic molecules.

It was identifying the targets such as those described herein may be useful, for example, in elucidating the biological function of the target protein, and for ameliorating body weight and/or eating disorders. In instances, for example, whereby a body weight and/or eating disorder situation results from a lower overall level of target protein expression and/or target protein activity in a cell or tissue involved in such a body weight and/or eating disorder, compounds that interact with the target protein may include ones which accentuate or amplify the activity of the bound target protein. Such compounds would bring about an effective increase in the level of target protein activity, thus ameliorating symptoms. In instances whereby mutations within the target gene cause aberrant target proteins to be made which have a deleterious effect that leads to a body weight and/or eating disorder, compounds that bind target protein may be identified that inhibit the activity of the bound target protein. Assays for testing the effectiveness of compounds, identified by, for example, techniques such as those described in Section 3.1 to 3.3, are discussed below, in Section 3.4.

### 3.1 In vitro screening assays for compounds that bind to the target proteins

In vitro systems may be designed to identify compounds capable of binding the target proteins of the invention. Compounds identified may be useful, for example, in modulating the activity of wild type and/or mutant target proteins, may be useful in elaborating the biological

function of the target protein, may be utilised in screens for identifying compounds that disrupt normal target protein interactions, or may in themselves disrupt such interactions.

5 The principle of the assays used to identify compounds that bind to the target protein involves preparing a reaction mixture of the target protein and the test compound under conditions and for a time sufficient to  
10 allow the two components to interact and bind, thus forming a complex which can be removed and/or detected in the reaction mixture. These assays can be conducted in a variety of ways. For example, one method to conduct such  
15 an assay would involve anchoring target protein or the test substance onto a solid phase and detecting target protein/test compounds complexes anchored on the solid phase at the end of the reaction. In one embodiment of  
20 such a method, the target protein may be anchored onto a solid surface, and the test compound, which is not anchored, may be labelled, either directly or indirectly.

In practice, microtiter plates may conveniently be utilised as the solid phase. The anchored component may be immobilised by non-covalent or covalent attachments.  
25 Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilised antibody, preferably a monoclonal antibody, specific for the  
30 protein to be immobilised may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the non-immobilised component is added to the coated surface containing the  
35 anchored component. After the reaction is complete,



4  
complexed components are removed, e.g. by washing, under  
conditions such that any complexed target will remain  
immobilised on the solid surface. The detection of  
complexes anchored on the solid surface can be  
accomplished in a number of ways. Where the previously  
non-immobilised component is pre-labelled, the detection of  
the label immobilised on the surface indicates that  
complexes were formed. Where the previously non-  
immobilised component is not pre-labelled, an indirect  
label can be used to detect complexes anchored on the  
surface, e.g. using a labelled antibody specific for the  
previously non-immobilised component (the antibody, in  
turn, may be directly labelled or indirectly labelled  
with a labelled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid  
phase, the reaction products separated from unreacted  
components, and complexes detected, e.g. using an  
immobilised antibody specific for target protein or the  
test compound to anchor any complexes formed in solution,  
and a labelled antibody specific for the other component  
of the possible complex to detect anchored complexes.

### 3.2 Assays for cellular proteins that interact with the target protein

Any method suitable for detecting protein-protein  
interactions may be employed for identifying novel target  
protein-cellular or extracellular protein interactions.  
These methods are outlined in Section 1.2, above, for the  
identification of pathway proteins, and may be utilised  
herein with respect to the identification of proteins  
which interact with identified target proteins.

### 3.3 Assays for compounds that interfere with target protein/cellular macromolecule interaction

The target proteins of the invention may, in vivo, interact with one or more cellular or extracellular macromolecules, such as proteins. Such macromolecules may include, but are not limited to, nucleic acid molecules and those proteins identified via methods such as those described above, in Section 3.2. For purposes of this discussion, such cellular and extracellular macromolecules are referred to herein as 'binding partners'. Compounds that disrupt such interactions may be useful in regulating the activity of the target protein, especially mutant target proteins. Such compounds may include, but are not limited to, molecules such as antibodies, peptides, and the like, as described, for example, in Section 3.1 above.

The basic principle of the assay systems used to identify compounds that interfere with the interaction between the target protein and its cellular or extracellular binding partner or partners involves preparing a reaction mixture containing the target protein, and the binding partner under conditions and for a time sufficient to allow the two to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of target protein and its cellular or extracellular binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the target protein and the cellular or extracellular binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound indicates that the compound interferes with the

interference with the target or with the interactive binding partner. Additionally, duplex formation within reaction mixtures containing the test compound and a mutant target protein. This phenomenon may be important in those cases wherein it is desirable to identify compounds that disrupt interactions of mutant and not normal target proteins.

The assay for compounds that interfere with the interaction of the target and binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the target protein or the binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction between the target protein and the binding partners, e.g. by competition, can be identified by conducting the reaction in the presence of the test substance, i.e. by adding the test substance to the reaction mixture prior to or simultaneously with the target protein and interactive cellular or extracellular binding partner. Alternatively, test compounds that disrupt pre-formed complexes, e.g. compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

In a heterogeneous assay system, either the target protein or the interactive cellular or extracellular

binding partner, is anchored onto a solid surface, while the non-anchored species is labelled, either directly or indirectly. In practice, microtiter plates are conveniently utilised. The anchored species may be immobilised by non-covalent or covalent attachments.

Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the target gene product or binding partner and drying.

Alternatively, an immobilised antibody specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the partner of the immobilised species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g. by washing) and any complexes formed will remain immobilised on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilised species is pre-labelled, the detection of label immobilised on the surface indicates that complexes were formed. Where the non-immobilised species is not pre-labelled, an indirect label can be used to detect complexes anchored on the surface, e.g. using a labelled antibody specific for the initially non-immobilised species (the antibody, in turn, may be directly labelled or indirectly labelled with a labelled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which inhibit complex formation or which disrupt pre-formed complexes can be detected.

Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound,

the reaction products are detected, e.g. using an antibody, and complex detected, e.g. using an immobilised antibody specific for one of the binding partners, and a complex formed in solution, and labelled with a probe for the other partner of the binding partners. Again, depending upon the order of addition of reactants to the liquid phase, test compounds which inhibit complex or which disrupt pre-formed complexes can be identified.

In an alternate embodiment of the invention, a homogeneous assay can be used. In this approach, a pre-formed complex of the target protein and the interactive cellular or extracellular binding partner is prepared in which either the target protein or its binding partners is labelled, but the signal generated by the label is quenched due to complex formation (see, e.g. US Pat. No. 4,109,496 by Rubenstein which utilises this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the pre-formed complex will result in the generation of a signal above background. In this way, test substances, which disrupt target protein/cellular or extracellular binding partner interaction, can be identified.

In a particular embodiment, the target protein can be prepared for immobilisation using recombinant DNA techniques described in Section 2.1 above. For example, the target protein gene coding region can be fused to a glutathione-S-transferase (GST) gene using a fusion vector, such as pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion protein. The interactive cellular or extracellular binding partner can be purified and used to raise a monoclonal antibody, using methods routinely practised in

the art and described above, in Section 3.1. This antibody can be labelled with the radioactive isotope  $^{125}\text{I}$ , for example, by methods routinely practised in the art. In a heterogeneous assay, e.g. the GST-target protein gene fusion protein can be anchored to glutathione-agarose beads. The interactive cellular or extracellular binding partner can then be added in the presence or absence of the test compound in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and the labelled monoclonal antibody can be added to the system and allowed to bind to the complexed components. The interaction between the target protein and the interactive cellular or extracellular binding partner can be detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured radioactivity.

Alternatively, the GST-target protein gene fusion protein and the interactive cellular or extracellular binding partner can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can be added either during or after the species are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the target protein/binding partner interaction can be detected by adding the labelled antibody and measuring the radioactivity associated with the beads.

In another embodiment of the invention, these same techniques can be employed using peptide fragments that correspond to the binding domains of the target protein.

5     the interactive cellular or extracellular binding  
 partner. In cases where the binding partner is a  
 protein, in place of one or more of the full length  
 proteins. Any number of methods routinely practised in  
 10     the art can be used to identify and isolate the binding  
 partner. These methods include, but are not limited to,  
 mutagenesis of the gene encoding one of the proteins and  
 screening for disruption of binding in a co-  
 immunoprecipitation assay. Compensating mutations in the  
 15     gene encoding the second species in the complex can then  
 be selected. Sequence analysis of the genes encoding the  
 respective proteins will reveal the mutations that  
 correspond to the region of the protein involved in  
 interactive binding. Alternatively, one protein can be  
 20     anchored to a solid surface using methods described in  
 this Section above, and allowed to interact with and bind  
 to its labelled binding partner, which has been treated  
 with a proteolytic enzyme, such as trypsin. After  
 washing, a short, labelled peptide comprising the binding  
 25     domain may remain associated with the solid material,  
 which can be isolated and identified by amino acid  
 sequencing. Also, once the gene coding for the cellular  
 or extracellular binding partner is obtained, short gene  
 segments can be engineered to express peptide fragments  
 30     of the protein, which can then be tested for binding  
 activity and purified or synthesised.

For example, and not by way of limitation, a target  
 protein can be anchored to a solid material as described  
 35     above, in this Section by making a GST-target protein  
 gene fusion protein and allowing it to bind to  
 glutathione agarose beads. The interactive cellular or  
 extracellular binding partner can be labelled with a  
 radioactive isotope, such as <sup>35</sup>S, and cleaved with a  
 40     proteolytic enzyme such as trypsin. Cleavage products

can then be added to the anchored GST-target protein gene fusion protein and allowed to bind. After washing away unbound peptides, labelled bound material, representing the cellular or extracellular binding partner binding domain, can be eluted, purified and analysed for amino acid sequence by well-known methods. Peptides so identified can be produced synthetically or fused to appropriate facilitative proteins using recombinant DNA technology.

### 3.4 Assays for amelioration of body weight and/or eating disorder symptoms

Any of the binding compounds, including but not limited to, compounds such as those identified in the foregoing assay systems, may be tested for the ability to prevent or ameliorate body weight and/or eating disorder symptoms, which may include, for example, obesity. Cell-based and animal model-based assays for the identification of compounds exhibiting such an ability to ameliorate body weight and/or eating disorder symptoms are described below.

First, cell-based systems such as those described above, in Section 2.2.2, may be used to identify compounds, which may act to prevent or ameliorate body weight and/or eating disorder symptoms. For example, such cell systems may be exposed to a compound, suspected of exhibiting an ability to ameliorate body weight and/or eating disorder symptoms, at a sufficient concentration and for a time sufficient to elicit a response in the exposed cells. After exposure, the cells are examined to determine whether one or more of the body weight and/or eating disorder-like cellular phenotypes has been altered to resemble a more normal or more wild type phenotype, or a phenotype more likely to produce a lower incidence or



*[The page contains faint, illegible bleed-through from the reverse side.]*

With regard to intervention, any treatments that reverse any aspect of body weight and/or eating disorder-like symptoms should be considered as candidates for human or companion animal body weight and/or eating disorder therapeutic intervention including the treatment of obesity. Dosages of test agents may be determined by deriving dose-response curves, as discussed in Section 1 below.

Similarly any treatments that can prevent the development or redevelopment of body weight and/or eating disorders should be considered as candidates for the prevention of human or companion animal body weight and/or eating disorder therapeutic intervention. Such disorders include, but are not limited to, obesity.

Protein expression patterns may be utilised in conjunction with either cell-based or animal-based systems to assess the ability of a compound to ameliorate body weight and/or eating disorder-like symptoms. For example, the expression pattern of one or more fingerprint proteins may form part of a fingerprint profile, which may then be used in such as assessment. Fingerprint profiles are described below, in Section 7.1. Fingerprint profiles may be characterised for known states, either body weight and/or eating disorder or normal states, within the cell- and/or animal-based model systems. Subsequently, these known fingerprint profiles may be compared to ascertain the effect a test compound has to modify such fingerprint profiles, and to cause the profile to more closely resemble that of a more desirable fingerprint. For example, administration of a compound may cause the fingerprint profile of a body weight and/or eating disorder model system to more closely resemble the control system. Administration of a compound may, alternatively, cause the fingerprint profile of a control system to begin to mimic a body weight and/or eating disorder state, which may, for example, be used in further characterising the compound of interest, or may be used in the generation of additional animal models.

#### 4. Compounds and methods for treatment of body weight and/or eating disorders

Described below are methods and compositions whereby body weight and/or eating disorder symptoms may be ameliorated. It is possible that body weight and/or eating disorders may be brought about, at least in part, by an abnormal level of target protein, or by the presence of a target protein exhibiting an abnormal activity. As such, the reduction in the level and/or activity of such target protein would bring about the

amelioration of body weight and/or eating disorder-like symptoms. The degree to which inhibition of target protein gene expression or level or target protein activity levels are discussed in Section 4.1 below.

Alternatively, it is possible that body weight and/or eating disorders may be brought about, at least in part, by the absence or reduction of the level of target protein expression, or a reduction in the level of target proteins activity. As such, an increase in the level of target protein gene expression and/or the activity of such proteins would bring about the amelioration of body weight and/or eating disorder-like symptoms. Techniques for increasing target protein gene expression levels or target protein activity levels are discussed in Section 4.2 below.

#### 4.1 Compounds that inhibit expression, synthesis or activity of mutant target proteins

As discussed above, target proteins involved in body weight and/or eating disorders may cause such disorders via an increased level of target protein activity. A variety of techniques may be utilised to inhibit the expression, synthesis, or activity of such target genes and/or proteins.

For example, compounds such as those identified through assays described above, in Section 3, which exhibit inhibitory activity, may be used in accordance with the invention to prevent or ameliorate body weight and/or eating disorder symptoms. As discussed in Section 3 above, such molecules may include, but are not limited to, peptides (such as, for example, peptides representing soluble extracellular portions of target protein transmembrane receptors, phosphopeptides, small organic

in inorganic molecules, or antibodies including, for example, polyclonal, monoclonal, humanised, anti-idiotypic, chimeric or single chain antibodies, and FAb, Fab' and FAb expression library fragments, and epitope-binding fragments thereof. Techniques for determination of effective doses and administration of such compounds are described below, in Section 6.1. Inhibitory antibody techniques are further described below, in Section 4.1.2.

Further, antisense and ribosome molecules, which inhibit expression of the target protein gene, may also be used in accordance with the invention to inhibit the aberrant target protein gene activity. Such techniques are described below, in Section 4.1.1; triple helix molecules may be utilised in inhibiting the aberrant target protein gene activity.

#### 4.1.1 Inhibitory antisense, ribosome and triple helix approaches

Among the compounds, which may exhibit the ability to prevent or ameliorate body weight and/or eating disorder symptoms are antisense, ribosome and triple helix molecules. Such molecules may be designed to reduce or inhibit either wild type, or if appropriate, mutant target protein gene activity. Techniques for the production and use of such molecules are well known to those of skill in the art.

Antisense RNA and DNA molecules act to directly block the translation of mRNA by hybridising to targeted mRNA and preventing protein translation. With respect to antisense DNA, oligodeoxy-ribonucleotides derived from the translation initiation site, e.g. between the -10 and +10 regions of the target gene nucleotide sequence of interest, are preferred.

These are also capable of RNA cleavage, capable of catalyzing the specific cleavage of RNA. For a review, see Fassi, D., 1994, Current Biology 4: 469-471. The ribosome is a large RNA molecule with sequence specific hybridization sites for all three types of complementary target RNA, i.e., with an endonucleolytic cleavage. The composition of ribosome molecules must include one or more sequences complementary to the target protein mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage. In this sequence, see U.S. Pat. No. 5,193,141, which is incorporated by reference herein in its entirety. As such, within the scope of the invention are engineered hammerhead motif ribosome molecules that specifically and efficiently catalyze endonucleolytic cleavage of RNA sequences encoding target proteins.

Specific ribosome cleavage sites within any potential RNA target are initially identified by scanning the molecule of interest for ribosome cleavage sites which include the following sequences, GUA, GGU and GUC. Once identified, short TNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target protein gene, containing the cleavage site may be evaluated for predicted structural features, such as secondary structure, that may render the oligonucleotide sequence unsuitable. The suitability of candidate sequences may also be evaluated by testing their accessibility to hybridise with complementary oligonucleotides, using ribonuclease protection assays.

Nucleic acid molecules to be used in triplex helix formation for the inhibition of transcription should be single stranded and composed of deoxynucleotides. The base composition of these oligonucleotides must be

designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either purines or pyrimidines to be present on a strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementary to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, containing a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.

Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a so-called "switchback" nucleic acid molecule. Switchback molecules are synthesised in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

Anti-sense RNA and DNA, ribosome and triple helix molecules of the invention may be prepared by any method known in the art for the synthesis of DNA and RNA molecules. They include techniques for chemically synthesising oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as, for example, solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the

antibodies. RNA or DNA. Such DNA sequences may be  
10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995

antibodies. RNA or DNA. Such DNA sequences may be  
10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995

Various well-known modifications to the DNA molecules may  
be introduced as a result of increasing intracellular  
stability and half-life. Possible modifications include,  
but are not limited to, the addition of flanking  
sequences or ribo- or deoxy-nucleotides to the 5' and/or  
3' ends of the molecule or the use of phosphorothioate or  
2' C-methyl rather than phosphodiesterase linkages within  
the oligodeoxy-ribonucleotide backbone.

#### 4.1.2 Antibodies for the inhibition of target protein

Antibodies that are both specific for target protein and  
interfere with its activity may be used to inhibit target  
protein function. Where desirable, antibodies specific  
for mutant target protein, which interferes with the  
activity of such mutant target product, may also be used.  
Such antibodies may be generated using standard  
techniques described in Section 2.3, supra, against the  
proteins themselves or against peptides corresponding to  
portions of the proteins. The antibodies include, but  
are not limited to, polyclonal, monoclonal, Fab  
fragments, single chain antibodies, chimeric antibodies,  
etc.

In instances where the target gene protein is  
intracellular and whole antibodies are used,  
internalising antibodies may be preferred. However,  
lipofectin or liposomes may be used to deliver the

antibody or a fragment of the Fab region, which binds to the target protein epitope into cells. Where fragments of the antibody are used, the smallest inhibitory fragment, which binds to the target protein's binding domain, is preferred. For example, peptides having an amino acid sequence corresponding to the domain of the variable region of the antibody that binds to the target protein may be used. Such peptides may be synthesised chemically or produced via recombinant DNA technology using methods well known in the art (e.g. see Creighton, 1983, supra; and Sambrook et al, 1989, supra).

Alternatively, single chain neutralising antibodies, which bind to intracellular target protein epitopes, may also be administered. Such single chain antibodies may be administered, for example, by expressing nucleotide sequences encoding single-chain antibodies within the target cell populating by utilising, for example, techniques such as those described in Marasco et al (Marasco, W. et al, 1993, Proc. Natl. Acad. Sci. USA, 90: 7889-7893).

In instances where the target protein is extracellular, or is a transmembrane protein, any of the administration techniques described below, in Section 6, which are appropriate for peptide administration may be utilised to effectively administer inhibitory target protein antibodies to their site of action.

#### 4.2 Methods for restoring target protein activity

Target proteins that cause body weight and/or eating disorders may be underexpressed within body weight and/or eating disorder situations. Alternatively, the activity of target protein may be diminished, leading to the development of body weight and/or eating disorder



...the level of target protein may be increased to levels which allow weight gain and/or eating disorder symptoms are prevented or ameliorated. The level of target protein may be increased, for example, by either increasing the level of target protein present or by increasing the level of active target protein, which is present.

For example, a target protein, at a level sufficient to ameliorate body weight and/or eating disorder symptoms may be administered to a patient exhibiting such symptoms. Any of the techniques discussed below, in Section 4, may be utilised for such administration. One of skill in the art will readily know how to determine the concentration of effective, non-toxic doses of the normal target protein, utilising techniques such as those described below, in Section 4.6.1.

Further, patients may be treated by gene replacement therapy. One or more copies of a normal target protein gene or a portion of the gene that directs the production of a normal target protein with target protein gene function, may be inserted into cells, using vectors which include, but are not limited to, adenovirus, adeno-associated virus, and retrovirus vectors, in addition to other particles that introduce DNA into cells, such as liposomes. Additionally, techniques such as those described above may be utilised for the introduction of normal target protein gene sequences into human cells.

Cells, preferably autologous cells, containing normal target protein gene sequences may then be introduced or reintroduced into the patient at positions which allow for the prevention or amelioration of body weight and/or

eating disorder symptoms. Such cell replacement techniques may be preferred, for example, when the target protein is a secreted, extracellular protein.

Additionally, antibodies may be administered which specifically bind to a target protein and by binding, serve to, either directly or indirectly, activate the target protein function. Such antibodies can include, but are not limited to, polyclonal, monoclonal, Fab fragments, single chain antibodies, chimeric antibodies and the like. The antibodies may be generated using standard techniques such as those described above, in Section 2.3, and may be generated against the protein themselves or against proteins corresponding to portions of the proteins. The antibodies may be administered, for example, according to the techniques described above, in Section 4.1.2.

## 5. Pharmaceutical preparations and methods of administration

The identified compounds, nucleic acid molecules and cells that affect target protein expression, synthesis and/or activity can be administered to a patient at therapeutically effective doses to prevent or to treat or to ameliorate body weight and/or eating disorders. A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms of body weight and/or eating disorder, including obesity, or alternatively, to that amount of a nucleic acid molecule sufficient to express a concentration of protein which results in the amelioration of such symptoms.

### 5.1 Effective dose

Toxicity and therapeutic efficacy of such compounds can

10. The compounds of the present invention are preferably in  
11. solid form. In experimental animals, e.g., in  
determining the  $ED_{50}$ , the compounds are orally effective at  
12. 100 mg/kg body weight. In humans, the  $ED_{50}$  of an  
13. compound is usually 100 mg/kg body weight. However,  
14. compounds with therapeutic effects in the therapeutic index  
15. are expressed as the ratio of  $ED_{50}$  to  $LD_{50}$ . Compounds  
16. which exhibit large therapeutic indices, are preferred.  
17. While compounds that exhibit toxic side effects may be  
18. used, care should be taken to design a delivery system  
19. that targets such compounds to the site of affected  
20. tissue in order to minimise potential damage to  
uninfected cells and, thereby, reduce side effects.

21. The data obtained from the cell culture assays and animal  
22. studies can be used in formulating a range of dosage for  
use in humans. The dosage of such compounds lies  
23. preferably within a range of circulating concentrations  
24. that include the  $ED_{50}$  with little or no toxicity. The  
25. dosage may vary within this range depending upon the  
dosage form employed and the route of administration  
utilised.

## 26. 5.2 Formulations and use

27. Pharmaceutical compositions for use in accordance with  
the present invention may be formulated in conventional  
28. manner using one or more physiologically acceptable  
carriers or excipients.

29. Thus, the compounds and their physiologically acceptable  
30. salts and solvates may be formulated for administration  
by inhalation or insufflation (either through the mouth  
or the nose) or oral, buccal, parenteral and rectal  
administration.

for oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pre-gelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl-cellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycolate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently

10 The compounds may be formulated for use in an inhaler or insufflator, e.g. in a metered dose inhaler, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dimethyl-tetrafluoroethane, or other suitable propellant. In the case of a 15 metered dose inhaler, the dose may be determined by providing a valve to deliver a metered amount. Capsules and cartridges (e.g. gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

20 The compounds may be formulated for parenteral administration by injection, e.g. by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, 25 solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

30 The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

35 In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation, for example, subcutaneously or intramuscularly or by intramuscular injection. Thus,

for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as blister pack. The pack or dispenser device may be accompanied by instructions for administration.

6. Diagnosis of the nature of body weight and/or eating disorder abnormalities including obesity

A variety of methods may be employed for the diagnosis of the nature of the body weight and/or eating disorders, the predisposition to body weight and/or eating disorders, and for monitoring the efficacy of any body weight and/or eating disorder compounds during, for example, clinical trials and for monitoring patients undergoing clinical evaluation for the treatment of such disorders.

The methods include conventional methods such as waist/hip ratios (BMI), weighing and c.t. or dexascans.

Obesity may be detected and the efficacy of treatment monitored by methods and parameters identified by such bodies as the World Health Organisation and the International Obesity Task Force.

Methods may also, for example, utilise reagents such as the fingerprint protein described in Section 4.1, and antibodies directed against differentially expressed and

1. The method of the present invention, in accordance with the present invention, comprises the steps of: (a) obtaining a sample of a body fluid or tissue from a patient; (b) detecting the presence or absence of a target protein in the sample; and (c) comparing the detected presence or absence of the target protein relative to the normal state.

15 The methods described herein may be performed, for example, by utilizing a reagent kit comprising a specific fingerprint protein or anti-fingerprint protein antibody reagent described herein, which may be conveniently used, e.g. in clinical settings, to diagnose patients exhibiting body weight and/or eating abnormalities.

20 Any cell type or tissue in which the fingerprint protein is expressed may be utilized in the diagnostics described below. Examples of suitable samples types include cell samples, tissue samples, and fluid samples such as blood, urine or plasma.

25 Among the methods, which can be utilised herein, are methods for monitoring the efficacy of compounds in clinical trials for the treatment of body weight and/or eating disorders. Such compounds can, for example, be compounds such as those described above, in Section 4. Such a method comprises detecting, in a patient sample, a protein, which is differentially expressed in the body weight and/or eating disorder state relative to its expression in a normal state.

30 During clinical trials, for example, the expression of a single fingerprint protein, or alternatively, a fingerprint pattern of a cell involved in a body weight and/or eating disorder can be determined in the presence

in absence of the compound being tested. The efficacy of the compound can be followed by comparing the expression data obtained to the corresponding known expression patterns in a normal state. Compounds exhibiting efficacy are those which alter the single fingerprint protein expression and/or the fingerprint pattern to more closely resemble that of the normal state.

The detection of the protein differentially expressed in a body weight and/or eating disorder state relative to their expression in a normal state can also be used for monitoring the efficacy of potential body weight and/or eating disorder compounds and compounds for the treatment of obesity during clinical trials. During clinical trials, for example, the level and/or activity of the differentially expressed protein can be determined in relevant cells and/or tissues in the presence or absence of the compound being tested. The efficacy of the compound can be followed by comparing the protein level and/or activity data obtained to the corresponding known levels/activities for the cells and/or tissues in a normal state. Compounds exhibiting efficacy are those which alter the pattern of the cell and/or tissue involved in the body weight and/or eating disorder to more closely resemble that of the normal state.

#### EXAMPLE 1

##### Mouse treatment protocol

Non-fasted lean and obese, 8 week old, female C57 B1/6J ob/ob mice were anaesthetised with 50% "Hyponovel" and 50% "Hyponorm" and then killed humanely with carbon dioxide gas. Liver was removed and snap frozen between tongs in liquid nitrogen. The tissues were lyophilised for 48h, crushed in a mortar with liquid nitrogen and the resultant dried powder stored at -80°C



### Protein solubilisation

For analysis of 1-2-PAM, 100 mg of homogenized liver was mixed with 1 ml of 10% (v/v) of a solution containing urea (8M), CHAPS (2% w/v), DTE (10mM), BTE (10mM), and 10% (v/v) of a solution of 10% (v/v) of a solution. A weighed portion of the final mixture (100 µl) was loaded into a sample cup at the cathodic end of the IPG gels.

### First dimension electrophoresis

17 A non-linear immobilised pH gradient of IPG strips (3.5-  
10.5 M) IPG 1000 was used as the first dimension. It  
offered high resolution, great reproducibility and  
allowed high protein loads. Based on specifications of  
the Geneva University Hospital, the non-linear pH  
18 gradient strips were prepared by Amersham-Pharmacia  
Biotechnology AB and are commercially available. The  
strips were 3mm wide and 165mm long.

20 Hydration of the IPG strips was performed overnight in a  
Pharmacia reswelling cassette with 25ml of a solution of  
urea (8M), CHAPS (2% w/v), DTE (10mM), Resolyte pH 3.5-10  
(2% v/v) and a trace of bromophenol blue.

25 When the rehydration cassette had been thoroughly emptied  
and opened, the strips were transferred to the Pharmacia  
strip tray. After placing IPG strips, humid electrode  
wicks, electrodes and sample cups in position, the strips  
and cups were covered with low viscosity paraffin oil.  
Samples were applied in the cups at the cathodic end of  
30 the IPG strips in a slow and continuous manner, without  
touching the gel.

The voltage was linearly increased from 500 to 3500 V  
during 3 hours, followed by 3 additional hours at 3500 V,  
31 whereupon the voltage was increased to 5000 V. A total

with your product of 100kV was used in an overnight run.

### Second dimension of the electrophoresis

After the first dimension run, the IPG strips were equilibrated in order to resolubilise the proteins and to reduce -S-S- bonds. The strips were thus equilibrated within the strip tray with 100ml of a solution containing Tris-HCl (50mM), pH 6.8, urea (6M), glycerol (30% v/v), SDS (2% w/v) and DTE (2% w/v) for 12 min. The SH groups were subsequently blocked with 100 ml of a solution containing Tris-HCl (50mM) pH 6.8, urea (6M), glycerol (30% v/v), SDS (2% w/v), iodoacetamide (2.5% w/v) and a trace of bromophenol blue for 5 min.

In the second dimension run, a vertical gradient slab gel with the Laemmli-SDS-discontinuous system was used with some small modifications, which may be summarised as follows:

- Gels are not polymerised in the presence of SDS. This seems to prevent the formation of micelles, which contain acrylamide monomer, thus increasing the homogeneity of pore size and reducing the concentration of unpolymerised monomer in the polyacrylamide. The SDS used in the gel running buffer is sufficient to maintain the necessary negative charge on proteins.
- Piperazine-diacrylyl (PDA) is used as crosslinker. This is believed to reduce N-terminal protein blockage, gives better protein resolution, and reduces diammine silver staining background.
- Sodium thiosulphate is used as an additive to reduce background in the silver staining of gels.

• 100% (w/v) in 10% (v/v) glycerol solution  
for 10 min at 4°C.

10 100% (w/v) in 10% (v/v) glycerol solution  
for 10 min at 4°C.

11 Running gel: 10% (w/v) in 10% (v/v) glycerol  
solution, 2-10% (v/v) in 10% (v/v) glycerol  
solution.

Stacking gel: No stacking.

12 Leading buffer: Tris-HCl, 1.0M, pH 4.5

Trailing buffer: Tris-glycine-SDS, 10mM-  
198mM-0.1% w/v, pH 8.3

Additives: Sodium trisulphate, 5mM

13 Polymerisation agents: TEMED (0.05%) APS (0.1%)

14 The gels were poured until 1.5 cm from the top of the  
plates and over-layered with sec-butanol for about two  
hours. After the removal of the overlay and its  
replacement with water the gels were left overnight.

20 After the equilibration, the IPG gel strips were cut to  
size. Six mm were removed from the anodic end and 14mm  
from the cathodic end. The second dimension gels were  
over-layered with a solution containing agarose (0.5%  
25 w/v) and Tris-glycine-SDS (10mM-198mM-0.1% w/v, pH 8.3  
heated at about 70°C and the IPG gel strips were  
immediately loaded through it.

30 The gel was run at 8-12°C for 8 hours at a constant  
current of 40mA/gel. The voltage is non-limiting, but  
usually requires 100 to 400 V.

### Staining

35 Silver staining, which is 100-fold more sensitive than  
Coomassie Brilliant Blue staining, was used (except where

otherwise stated. Thus, the 1-13% gels were stained with an ammoniacal silver staining as follows:

All steps were performed on an orbital shaker at 50 rpm.

Step 1: At the end of the second dimension run, the gels were removed from the glass plates and washed in deionised water for 5 min.

Step 2: The gels were soaked in ethanol:acetic acid:water (40:10:50 volume ratio) for 1 hour.

Step 3: The gels were soaked in ethanol:acetic acid:water (5:5:90 volume ratio) for 2 hours or overnight.

Step 4: They were washed in deionised water for 5 min.

Step 5: They were soaked in a solution containing glutaraldehyde (1% w/v and sodium acetate (0.5M) for 30 min.

Step 6: They were washed 3 times in deionised water for 10 min.

Step 7: In order to obtain homogenous dark brown staining of proteins, gels were soaked twice in a 2, 7-naphthalenedisulphonic acid solution (0.05% w/v) for 30 min.

Step 8: The gels were then rinsed 4 times in deionised water for 15 min.

Step 9: The gels were stained in a freshly made ammoniacal silver nitrate solution for 30 minutes. To prepare 750ml of this solution, 6g of silver nitrate were dissolved in 30ml of deionised water, which was slowly mixed into a solution containing 160ml of water, 10ml of concentrated ammonia (25%) and 1.5ml of sodium hydroxide (10N). A transient brown precipitate might form. After it cleared, water was added to give the final volume.

Step 10: After staining, the gels were washed 4 times in deionised water for 4 min.

Step 11: The images were developed in a solution of

[illegible]

II''

check and lean mine spot detection, quantitation and matching, gel image extraction, zooming, warping and printing as well as gel stacking and flipping were carried out with the "Meltview" program.

2025

— — — — —

— 23 —

LOM 16  
LOM 17  
LOM 21  
LOM 22  
LOM 23  
LOM 24  
LOM 25  
LOM 26  
LOM 27  
LOM 28  
LOM 29

The drawings are presented to show the location of the DEPs by reference to Figure 1 and the differential expression in Figures 2-8.

The locations are shown in the maps of Figures 1A - 1E, in which Figure 1E shows the entire map from the 2-D-PAGE of liver tissue of lean mice. (It so happens that all the differentially expressed proteins identified are over-expressed in the lean control mice, relative to the ob/ob control mice.) The map is divided into four quadrants in the manner:

|         |         |
|---------|---------|
| Fig. 1A | Fig. 1E |
| Fig. 1C | Fig. 1F |

in which the pI runs from left (low pI) to right (high pI) and the relative molecular mass from top to bottom, so that the quadrant of Figure 1A shows the spots corresponding to proteins of the lowest pI and highest relative molecular mass and the quadrant of Figure 1C those of the highest pI and lowest relative molecular mass. The DEPs are marked as LOM16, LOM17, LOM18, LOM19, LOM20, LOM 21, LOM22, LOM23, LOM24, LOM25, LOM26, LOM27, LOM28, and LOM29. The other spots identified are

The following table shows the characteristics of the 29 DEP spots from liver of obese mice. The spots are numbered according to their position in the 2D gel, and their corresponding accession number, and linking to the gene. The following table shows the characteristics of the 29 DEP spots from liver of obese mice, area, and optical densities and apparent pI and relative molecular mass.

Table 1: DEP spots from liver of obese mice

|    | ID    | % Vol. | Area   | CF    | pI   | RMM    |
|----|-------|--------|--------|-------|------|--------|
|    | LOM16 | 0.177  | 1.471  | 1.46  | 6.33 | 160000 |
|    | LOM17 | 0.034  | 0.684  | 0.891 | 8.61 | 90000  |
|    | LOM18 | 0.059  | 0.954  | 0.967 | 6.84 | 82896  |
|    | LOM19 | 0.370  | 3.154  | 1.414 | 8.31 | 58000  |
| 11 | LOM20 | 0.298  | 2.609  | 1.433 | 8.83 | 56420  |
|    | LOM21 | 0.409  | 3.307  | 1.473 | 6.31 | 49971  |
|    | LOM22 | 0.283  | 2.324  | 1.431 | 6.28 | 40937  |
|    | LOM23 | 0.248  | 1.961  | 1.534 | 6.80 | 36508  |
|    | LOM24 | 0.293  | 2.419  | 1.461 | 6.83 | 32671  |
| 21 | LOM25 | 0.388  | 3.277  | 1.439 | 6.26 | 26266  |
|    | LOM26 | 0.299  | 2.664  | 1.398 | 8.10 | 24200  |
|    | LOM27 | 0.169  | 2.174  | 1.012 | 7.17 | 15283  |
|    | LOM28 | 1.495  | 10.596 | 1.655 | 9.07 | 13016  |
|    | LOM29 | 0.255  | 2.756  | 1.200 | 6.33 | 11946  |

Table 2: Reference spots from liver of obese control mice

|    | ID     | % Vol. | Area  | OD    | Pi   | RMM    |
|----|--------|--------|-------|-------|------|--------|
| 1  | P99015 | 0.121  | 1.152 | 1.275 | 6.31 | 160851 |
|    | P99015 | 0.127  | 1.470 | 1.460 | 6.35 | 160851 |
|    | P99015 | 0.161  | 0.766 | 1.070 | 6.17 | 160851 |
|    | P99015 | 0.098  | 1.041 | 1.252 | 6.22 | 160851 |
|    | P99015 | 0.157  | 1.715 | 1.302 | 6.26 | 160000 |
| 10 | Q05920 | 0.088  | 1.133 | 1.050 | 6.16 | 121447 |
|    | Q05920 | 0.039  | 0.643 | 0.803 | 6.10 | 121447 |
|    | Q05920 | 0.201  | 2.260 | 1.281 | 6.21 | 120000 |
|    | POS113 | 0.023  | 0.306 | 0.981 | 4.87 | 90604  |
|    | POS113 | 0.082  | 0.827 | 1.214 | 4.89 | 89679  |
| 15 | P08113 | 0.028  | 0.337 | 0.911 | 4.89 | 90000  |
|    | P99017 | 0.011  | 0.766 | 0.176 | 5.42 | 90604  |
|    | P99017 | 0.020  | 1.194 | 0.226 | 5.52 | 90000  |
|    | P99017 | 0.034  | 0.088 | 0.598 | 5.61 | 90000  |
|    | P99017 | 0.094  | 1.317 | 0.077 | 5.68 | 89359  |
| 20 | P99017 | 0.020  | 0.898 | 0.298 | 5.77 | 90000  |
|    | P11499 | 0.033  | 0.766 | 0.669 | 5.02 | 82305  |
|    | P37040 | 0.020  | 0.674 | 0.465 | 5.28 | 71490  |
|    | P37040 | 0.008  | 0.429 | 0.226 | 5.25 | 71299  |
|    | P20029 | 0.030  | 0.735 | 0.553 | 4.99 | 70356  |
| 25 | P20029 | 0.074  | 0.919 | 1.072 | 5.01 | 70169  |
|    | P20029 | 0.433  | 3.951 | 1.391 | 5.04 | 69426  |
|    | P38647 | 0.044  | 1.102 | 0.539 | 5.29 | 69426  |
|    | P38647 | 0.011  | 0.643 | 0.200 | 5.27 | 69426  |
|    | P38647 | 0.067  | 1.133 | 0.861 | 5.32 | 69057  |
| 30 | P38647 | 0.266  | 2.909 | 1.273 | 5.34 | 68690  |
|    | P16627 | 0.027  | 1.164 | 0.317 | 5.25 | 67781  |
|    | P16627 | 0.066  | 0.949 | 0.970 | 5.27 | 67421  |
|    | P16627 | 0.367  | 3.675 | 1.304 | 5.30 | 67063  |
|    | P07724 | 0.020  | 0.888 | 0.343 | 5.68 | 66707  |
| 35 | P07724 | 0.133  | 1.378 | 1.256 | 5.79 | 66529  |
|    | P07724 | 0.038  | 1.072 | 0.469 | 5.42 | 66000  |



| IE      | % Vol. | Area  | CI    | FI   | RMM   |
|---------|--------|-------|-------|------|-------|
| F000000 | 1.116  | 1.181 | 1.187 | 5.4  | 85070 |
| F14730  | 1.12   | 1.764 | 1.304 | 5.4  | 6551  |
| F14210  | 1.157  | 2.123 | 1.117 | 4.48 | 59617 |
| F10000  | 1.17   | 1.772 | 1.111 | 5.20 | 58244 |
| F19000  | 1.371  | 3.118 | 1.403 | 5.01 | 5411  |
| F14000  | 1.131  | 1.411 | 1.101 | 5.47 | 58144 |
| F14210  | 1.123  | 1.843 | 1.041 | 4.48 | 58574 |
| F17770  | 0.177  | 1.317 | 0.993 | 5.71 | 56420 |
| F17770  | 0.208  | 2.833 | 1.453 | 5.83 | 56420 |
| F19100  | 0.421  | 3.240 | 1.411 | 4.50 | 55496 |
| F09100  | 0.059  | 0.881 | 0.830 | 4.82 | 55803 |
| F09100  | 0.114  | 1.001 | 1.421 | 4.81 | 55496 |
| F09010  | 0.090  | 1.070 | 1.080 | 5.71 | 54588 |
| F02651  | 0.051  | 0.827 | 0.783 | 5.11 | 53641 |
| F04104  | 0.043  | 1.041 | 0.851 | 5.84 | 53246 |
| F20100  | 0.021  | 0.501 | 0.870 | 5.11 | 53039 |
| F56480  | 0.054  | 1.071 | 0.884 | 4.91 | 49838 |
| F56480  | 0.137  | 1.403 | 1.318 | 5.01 | 49561 |
| F56480  | 0.446  | 3.553 | 1.470 | 5.05 | 49152 |
| F17180  | 0.468  | 3.706 | 1.542 | 6.34 | 46771 |
| F05784  | 0.038  | 1.011 | 0.497 | 5.15 | 46771 |
| F05784  | 0.083  | 1.501 | 0.737 | 5.20 | 46771 |
| F05784  | 0.130  | 1.654 | 1.056 | 5.26 | 46642 |
| F09759  | 0.074  | 1.070 | 1.017 | 5.86 | 44260 |
| F99021  | 0.318  | 2.693 | 1.390 | 5.25 | 42000 |
| F99022  | 0.064  | 0.827 | 1.093 | 5.27 | 42230 |
| F99016  | 0.160  | 1.713 | 1.213 | 6.43 | 41168 |
| F35500  | 0.410  | 3.093 | 1.631 | 6.77 | 40985 |
| F14200  | 0.110  | 1.501 | 0.991 | 4.81 | 40985 |
| F99014  | 0.017  | 1.184 | 1.171 | 5.27 | 40620 |
| Q64374  | 0.484  | 4.104 | 1.837 | 5.08 | 33929 |
| F80481  | 0.058  | 0.821 | 1.311 | 6.78 | 32060 |
| F16011  | 1.493  | 9.790 | 1.720 | 6.93 | 28148 |
| F16011  | 0.560  | 4.160 | 1.870 | 6.84 | 27855 |

| IL     | % Vol. | Area  | OF    | PI   | RMM   |
|--------|--------|-------|-------|------|-------|
| P16010 | 0.034  | 1.909 | 1.411 | 4.76 | 27914 |
| P01408 | 0.071  | 1.409 | 0.689 | 4.70 | 26711 |
| Q00623 | 0.027  | 1.077 | 0.143 | 5.45 | 24664 |
| Q00623 | 0.054  | 1.592 | 0.475 | 5.27 | 24202 |
| P14701 | 0.077  | 1.746 | 0.588 | 4.81 | 24050 |
| P02762 | 0.103  | 1.770 | 1.197 | 4.80 | 19046 |
| P02762 | 0.305  | 2.542 | 1.461 | 4.89 | 19046 |
| P99014 | 0.044  | 3.553 | 0.150 | 4.05 | 14659 |
| P80395 | 0.236  | 3.030 | 1.069 | 4.63 | 14567 |
| P08227 | 0.468  | 4.348 | 1.316 | 6.11 | 14537 |
| P12787 | 0.224  | 2.848 | 1.046 | 4.91 | 12433 |
| P16045 | 0.173  | 2.634 | 0.915 | 5.06 | 12381 |
| P12710 | 0.255  | 2.756 | 1.200 | 6.33 | 11946 |

The positions of some of the DEPs coincide with those of reference spots. Sequencing will be undertaken to check whether they are actually the same.

Referring now to Figures 2-8, these Figures show images of lean controls (left) and ob/ob ("obese") controls (right) relating to one mouse. It should be appreciated that these images cannot fully represent to the eye the differences in expression measurable by computer. Thus, underneath, a bar chart is provided in which the volume of the spot as a percentage of the total volume of all spots is shown on the y-axis. All bar charts relate to 4 mice and resulted from a student T test ( $P < 0.01$ ).

#### Preparative 2-D-PAGE

The analytical 2-DGE described above was repeated, with the following changes. Four mg of dried liver was mixed with 450 microlitres of the solubilisation solution and loaded into the IPG strips by in-gel rehydration.

After the first dimension run, the gels were  
soaked in deionized water for 3 min. and then in transfer buffer.

### Protein electroblotting

The blotting of proteins separated by 2-D-PAGE onto  
polyvinylidene difluoride (PVDF) membranes has enabled  
the identification and characterization of proteins from  
complex biological samples. Transfer of the proteins  
can be carried out using several methods such as vacuum,  
capillary or electric field. Electrobloeting, using  
vertical buffer tanks or a semi-dry method, is preferred.  
Both techniques can use the 3-(3-morpholino)propane-  
sulfonic acid (MOPS) transfer buffer. Gloves  
must be worn and all filter papers should be washed  
three times for 3 min. in water and three times in  
transfer buffer. These two steps are important in order  
to avoid any protein or amino acid contamination.

The procedure was as follows. After second-dimensional  
electrophoresis, the gels were soaked in deionized water  
for 3 min. Then they were equilibrated in a solution  
containing 10mM CAPS pH 11 for 30 min. At the same  
time, PVDF membranes were wetted in methanol for 1 min  
and equilibrated in a solution containing 10mM CAPS pH  
11 and methanol (10% v/v) also for 30 min.  
Electroblotting was carried out in a semi-dry apparatus  
with a solution containing 10mM CAPS pH 11 and methanol  
(20% v/v anodic side; 5% v/v cathodic side) at 1 mA/cm<sup>2</sup>  
constant current for 3 hours at 15°C.

### Protein detection on PVDF membranes

Amido Black and Coomassie Brilliant Blue R-250 were used  
instead of silver staining to visualise proteins on PVDF  
membranes and are compatible with the ensuing post-  
separation analysis. Thus, in another 2-D-PAGE run, after

electrotransfer, the PVDF membranes were stained in a solution containing Amido black (0.5 w/v), isopropanol (25% v/v), and acetic acid (10% v/v) for 1 min. Destaining was done by several washings in deionized water.

In another run, after electrotransfer, the PVDF membranes were stained in a solution containing Coomassie Brilliant Blue R-250 (0.1 w/v) and methanol (50% v/v) for 15 min. Destaining was done in a solution containing methanol (40% v/v) and acetic acid (10% v/v). The same method was used for preparative gels that did not need electrotransfer for further post-separation analysis, such as peptide mass fingerprinting.

The PVDF stained membranes were either air-dried or dried on a 3mm thick plate onto a heating plate at 37°C for 10 min.

### Scanning

This was done as described above.

### Protein identification

In amino sequence analysis by Edman degradation, amino acid derivatives are sequentially cleaved one at a time from the protein. Proteins with a chemically inaccessible alpha-amino group cannot be sequenced directly by this procedure and are termed N-terminally blocked. The best way to overcome the blocked proteins is to generate individual fragments by chemical or proteolytic cleavage. Routinely, ten to twelve Edman degradation cycles were performed for each spot. A search in the SWISS-PROT database was made to detect identity to known protein sequences.

The Amino Acid Analysis protocol was carried out with  
1000 µl and N-terminal sequencing was performed  
using an ABI model 473A or 477A microsequencer with  
Applied Biosystems reagents and "1000 µl" cartridge.

For internal sequencing, the 10 µl of interest were  
excised and placed for two hours in a solution  
containing acetic acid (100mM), methanol (10% v/v) and  
PVDF (1% v/v) at 37°C. After three washes in distilled  
water, the PVDF spots were cut into small pieces (approx  
1mm<sup>2</sup>) and incubated in 10 microlitres of a solution  
containing sodium phosphate (100mM pH 8.0 and lysyl  
endopeptidase (1 microgram). Following overnight  
digestion at room temperature, guanidine-HCl (20 mg) and  
15 DTT (100 micrograms) were added. After reduction for 1  
hour at 37°C, the mixture was incubated for 30 min, at  
room temperature, with 300 micrograms of iodoacetamide.  
The digestion solution was removed and kept. PVDF  
pieces were then extracted overnight with 25 microlitres  
20 of a solution containing isopropanol (70% v/v) and  
trifluoroacetic acid (5% w/v). This elution solution  
was removed and the PVDF was washed twice with 60  
microlitres of TFA (0.1% w/v). The digestion and  
elution solutions were pooled together with two final  
25 washes and this mixture was separated by two-dimensional  
reverse phase HPLC and sequence determination performed.

### Immunoblotting

PVDF membranes were first stained to visualise proteins,  
30 following which the immunodetection was undertaken.  
This allowed matching of proteins detected with ECL  
against those detected with the non-specific protein  
stain through computer comparison of both images. The  
mechanical strength of PVDF was also exploited as the  
35 same 2-D gel can be used many times for different

antibodies.

The whole procedure was carried out in a rotating oven at 4°C temperature. The use of a nucleic acid probe hybridiser tube minimised the volumes and costs.

- The membranes were blocked in 10 ml of a solution of 30 PBS (pH 7.2) and non-fat dry milk (5% w/v) for 30 min.  
10
- The membranes were then incubated in 10 ml of a solution containing PBS-"Tween" 20 (0.5% v/v), non-fat dry milk (5% w/v) and the primary antibody/antibodies (1:100 or greater, depending on the antibody) for 2 hours.  
15
- Three quick rinses were performed with 10 ml of PBS-"Tween" 20 (0.5% v/v) and then the membranes were washed for 3 x 10 min with 10 ml of PBS-"Tween" 20 (0.5% v/v).  
20
- The membranes were incubated in 10 ml of a solution containing PBS-"Tween" 20 (0.5% v/v), non-fat dry milk (5% w/v) and the secondary peroxidase-conjugated antibody (1:1000; for example, if the primary antibody was sheep anti-mouse, then goat anti-sheep IgG was used as the secondary antibody) for 1 hour.  
25
- Three quick rinses were performed with 10 ml of PBS-"Tween" 20 (0.5% v/v) and then the membranes were washed for 5 x 10 min with 10 ml of PBS-"Tween" 20 (0.5% v/v).  
30
- After the last wash, the membranes were transferred  
35

1. The gel was stained with Coomassie Brilliant Blue G250 (Bio-Rad) for 1 hour. The gel was then stained with 0.1% methanol and 0.1% acetic acid for 1 hour.

2. The gel was developed with 0.1% silver nitrate (Bio-Rad) for 1 hour. The gel was then wrapped in "Kodak" film and exposed for 1 hour. The film was then developed with 0.1% silver nitrate (Bio-Rad) for 1 hour.

3. An X-ray film was then exposed in a dark room for 1 hour. The film was then developed with 0.1% silver nitrate (Bio-Rad) for 1 hour.

### Peptide mass fingerprinting

The 2-DE method was repeated, but using a Coomassie blue stain. The 2-DE spots were destained with 10 microlitres of 30% acetonitrile in 50mM ammonium bicarbonate at 37°C for 48 min. The supernatant was discarded and the gel spots dried in a "SpeedVac" for 1 min. The gel spots were rehydrated with 25 microlitres of a solution containing 0.2 micrograms of porcine trypsin and 50mM ammonium bicarbonate for 2 hours at 35°C. Then the gel spots and supernatant were dried in a "SpeedVac" for 30 min, rehydrated with 20 microlitres of H<sub>2</sub>O for 30 min at 35°C and dried again for 30 min. Twenty microlitres of a solution of 50% of acetonitrile and 0.1% of TFA was added to the spots and sonicated for 10 min. Two microlitres of the supernatants was loaded in each well of a 96 or 400 MALDI target plate. The samples were air-dried. Then 2 microlitres of a solution containing 4 mg/ml of alpha-cyano-4-hydroxycinnamic acid, 50% acetonitrile and 0.1% TFA was added to each well and air-dried.

The peptide mixtures were analysed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Perseptive Biosystems Voyager Elite MALDI-

TEP-M3 with a nitrogen laser (331nm) and operated in reflection delayed extraction mode.

Protein identification has been carried out using "Peptide" (<http://www.expasy.ch/tools/peptide.html>). It is a tool that allows the identification of proteins using pI, relative molecular mass and peptide mass fingerprinting data. Experimentally measured, user-specified peptide masses were compared with the theoretical peptides calculated for all proteins in the SWISS-PROT/TREMBL databases.

#### MS/MS sequencing

When protein identification was not successful with the peptide mass fingerprinting procedure, the supernatant of digested spots was desalted in "ZipTip" C18 pipette tips (Millipore) and eluted with 50% acetonitrile and 0.1% TFA. Peptides were applied by nanoflow (in-house nanospray) sample introduction to a tandem mass spectrometer that consists of two quadrupoles and an orthogonal time of flight tube (Q-TOF) from MicroMass (UK). Fragment ion spectra were interpreted with the MOWSE database search (<http://www.segnet.dl.ac.uk/mowse.html>).

#### Data management: The mouse SWISS-2-DPAGE database

SWISS-2-DPAGE is an annotated 2-D-PAGE database in which all the data are easily retrieved by computer programs and stored in a format similar to that of the SWISS-PROT Protein Sequence Database, one of the most updated and annotated protein sequence databases presently available. The SWISS-2-DPAGE database assembles data on proteins identified on various 2-D-PAGE maps. Each SWISS-2-DPAGE entry contains data on one protein, including mapping procedures, physiological and pathological data and bibliographical references, as



Western blot analysis of 2-D PAGE images showing the protein  
expression profile. The protein expression profile is provided in SWISS-2D PAGE  
and, through the Internet, the protein database (EMBL,  
Genbank, EMBL, etc.). The database has been  
updated in 1997 (World Wide Web Server).

<http://www.expasy.ch/>. Worldwide, scientists using  
the 2-D PAGE protocols (normalised pH gradient or  
normalised isoelectric separation) are now able to compare  
their images with SWISS-2D PAGE data.

## EXAMPLE 2

The method of Example 1 was repeated, substituting for  
the liver tissue 100 micrograms (analytical scale) or 4  
mg (preparative scale) of dried gastrocnemius muscle  
tissue and using the same respective volumes of the  
protein-solubilising solution as in Example 1. A 2-D PAGE  
map was thus obtained, from which DEPs were identified  
and isolated.

The muscle DEPs were:

MOM 31

MOM 32

MOM 34

MOM 36

which were underexpressed in ob/ob mouse skeletal muscle  
relative to expression in lean mouse skeletal muscle and

MOM 33

MOM 35

which were overexpressed in ob/ob skeletal muscle  
relative to lean. These are shown in Figures 9-11  
inclusive.

The location of the DEPs has been determined by running  
the liver extract from lean mice in the same gel as the  
muscle extract, so that liver protein reference spots

appeared in the same position as in the reference spots.

### EXAMPLE 3

The method of Example 1 was repeated, substituting for the liver tissue 16mg (analytical scale) or 160mg (preparative scale) of white adipose tissue and using the same respective volumes of the protein-solubilising solution as in Example 1. A 2-DGF map was thus obtained, from which DEPs were identified and isolated.

The location of the proteins has been determined by running the liver extract from lean mice in the same gel as the white adipose extract, so that the liver protein reference spots appear in the white adipose extract gel to serve as reference spots for the latter also.

The following differentially expressed proteins are underexpressed in ob/ob mouse adipose tissue relative to lean mouse adipose tissue:

|        |        |        |
|--------|--------|--------|
| WOM 37 | WOM 52 | WOM 60 |
| WOM 38 | WOM 53 | WOM 61 |
| WOM 44 | WOM 54 | WOM 62 |
| WOM 45 | WOM 55 | WOM 63 |
| WOM 48 | WOM 57 | WOM 64 |
| WOM 49 | WOM 58 |        |
| WOM 50 | WOM 59 |        |

The following differentially expressed proteins were overexpressed in obese mouse adipose tissue relative to adipose tissue of lean mice:

WOM 39  
WOM 40  
WOM 41  
WOM 42

W.M. 4

W.M. 4

W.M. 4

W.M. 4

The following is a summary of the results of the experiments.

#### EXAMPLE 4

The results of Example 1 was repeated, substituting the liver tissue 41. micrograms (analytical scale) of dry preparative scale of brown adipose tissue and using the same respective volumes of the protein-solubilising solution as in Example 1. The weight of sample loaded was 180 micrograms (analytical) or 1.8mg (preparative). A 2-DGE map was thus obtained, from which DEPs were identified and isolated.

The location of the proteins has been determined by running the liver extract from lean mice in the same gel as the brown adipose extract, so that the liver protein reference spots appear in the brown adipose extract gel to serve as reference spots for the latter also.

The brown adipose tissue DEPs which are overexpressed in ob/ob mouse brown adipose tissue relative to lean mouse brown adipose tissue are:

BOM 66

BOM 67

BOM 68

BOM 75

BOM 76

BOM 77

The brown adipose tissue DEPs that are underexpressed in ob/ob mouse brown adipose tissue relative to lean mouse adipose tissue are:

BOM 70  
BOM 71  
BOM 72  
BOM 73  
BOM 74

These are shown in Figures 24-29 inclusive.

EXAMPLE 5

10 Lean mice and obese mice, either fed ad-lib or fasted  
overnight were anaesthetised with 50% hypnovel and 50%  
hypnorm and then killed humanely with carbon dioxide  
gas. The hypothalamus was removed and frozen in liquid  
15 nitrogen. The method of example 1 was then followed but  
using 200mg of hypothalamic tissue rather than 200mg  
liver.

The references mentioned herein are all expressly  
incorporated by reference.

Claims:

1. A method of screening an agent to determine its ability to convert the expression of differentially expressed protein towards that of a normal subject having a more normal body weight or eating behaviour, the method comprising:

a. obtaining a sample of relevant tissue taken from a representative of a subject having differential body weight or eating disorders; and

b. determining the presence, absence or degree of expression of the differentially expressed protein or proteins in the tissue from a representative of the treated subjects; and

c. selecting or rejecting the agent according to the extent to which it changes the expression of the differentially expressed protein or proteins in the treated subject having body weight or eating disorders.

2. The method of claim 1, wherein the agent is selected if it converts the expression of the differentially expressed protein towards that of a subject having a more normal body weight or eating behaviour.

3. The method of claim 1 or claim 2, wherein the agent is selected if it converts the expression of the protein or proteins to that of the normal subject.

4. The method of any one of claims 1 to 3, wherein the body weight or eating disorder is a result of a disorder which causes an increase in body weight and/or which is

associated with an excess in food consumption.

4. The method of any one of the preceding claims, wherein the paradigm is based on tissue from obese subjects and normal subjects.

5. A method of any of claims 1 to 4, wherein the body weight and/or eating disorder is a result of a disorder which causes a reduction in body weight and/or which is associated with a low food intake.

6. A method of claim 5, wherein the paradigm is based on tissue from subjects with anorexia nervosa or bulimia or AIDS or cancer and normal subjects.

7. The method of claim 1, wherein the paradigm is based on animals which are models of obesity as a result of a genetic mutation such as ob/ob, db/db, agouti, fat, tub, fa/fa together with lean littermates.

8. The method of claim 1, wherein the paradigm is based on animals in which obesity is induced or exacerbated by dietary treatment.

9. The method of claim 1, wherein the paradigm is based on desert rodents such as spiny mice or sand rats, which develop obesity on normal laboratory diets.

10. The method of claim 1, wherein differential levels of obesity occur in apparently similar animals in which it is attempted to induce obesity by dietary modification.

11. The method of any one of the preceding claims, wherein in the paradigm, the subjects having

1. A method for the treatment of obesity, comprising the steps of:  
a) determining the body weight of a subject;  
b) comparing the body weight of the subject with a normal body weight;  
c) if the body weight of the subject is greater than the normal body weight, administering to the subject a drug, dietary restriction or exercise, or a combination thereof, to reduce the body weight of the subject to the normal body weight.

2. The method of claim 1, wherein the drug is a thermogenic drug, an anorexic drug, or a combination thereof, or a combination thereof with dietary restriction or exercise, or a combination thereof with dietary restriction or exercise.

3. The method of claim 1, wherein the drug is a thermogenic drug, an anorexic drug, or a combination thereof, or a combination thereof with dietary restriction or exercise, or a combination thereof with dietary restriction or exercise, wherein the subjects having differential levels of body weight comprise normal subjects and subjects having a below normal body weight.

4. The method of claim 1, wherein the body weight of a subject is reduced by treatment with a drug, dietary restriction or exercise.

5. The method of claim 1, wherein the drug is a thermogenic drug.

6. The method of claim 1, wherein the thermogenic drug is a  $\beta$ -adrenoceptor agonist.

7. The method of claim 1, wherein the drug is an anorexic drug.

8. The method of claim 1, wherein the anorexic drug is sibutramine or fenfluramine.

9. The method of claim 1, wherein the paradigm is based on animals, which are fed, fasted or starved.

10. The method of any one of the preceding claims,

wherein in the paradigm, the subjects having differential levels of protein expression comprise: normal subjects and underweight or overweight subjects.

20. The method of any one of the preceding claims, wherein in the paradigm, the subjects having differential levels of protein expression comprise:

(a) normal subjects and underweight or overweight subjects; and

(b) underweight or overweight subjects which have not been treated with the agent and underweight or overweight subjects which have been treated with the agent.

21. The method of claim 20, wherein the differential levels of protein expression are not observed in normal subjects who have and have not been treated with the agent.

22. The method of any one of the preceding claims, wherein in the paradigm, the subjects having differential levels of protein expression comprise:

(a) normal subjects who have and have not been treated with the agent; and

(b) subjects having body weight and/or eating disordered function who have and have not been treated with the agent.

23. The method of claim 22, wherein the differential levels of protein expression are not observed in normal subjects and subjects having body weight and/or eating disordered function, both groups of subject being untreated with the agent.

24. The method of any one of the preceding claims,



method of claim 1, further comprising the step of: isolating a protein from a cell-free extract of the cell, the protein being a protein that is secreted by the cell.

11. The method of any one of the preceding claims, further comprising the step of: isolating a protein from a cell-free extract of a cell, the protein being a protein that is secreted by the cell.

12. The method of claim 10, further comprising the step of: characterizing the isolated protein.

13. The method of claim 11, further comprising using the protein in an assay for specific binding partners of the protein.

14. The method of claim 11, further comprising using the protein in an assay to screen for agonists or antagonists of the protein.

15. The method of any one of claims 1 to 14, wherein the agents or proteins are screened using a high throughput screening method.

16. A method of making a pharmaceutical composition, which comprises having identified an agent using the method of any one of claims 1 to 14, the further step of: manufacturing the agent and formulating it with an acceptable carrier to provide the pharmaceutical composition.

17. Use of an agent identified by the method of any one of claims 1 to 14 for the preparation of a medicament for the treatment of a condition characterised by abnormal weight and/or eating dysfunction.

34. The use of claim 33 wherein the condition is obesity, non-insulin dependent diabetes, anorexia nervosa, bulimia or cachexia induced by AIDS or cancer or trauma.

5

35. A method of treating a condition characterised by body weight and/or eating dysfunction in a patient, the method comprising administering a therapeutically or prophylactically effective amount of such an agent identified by a method of any one of claim 1 to 26 to the patient.

36. The method of claim 35, wherein the body weight and/or eating dysfunction is a result of obesity, non-insulin dependent diabetes or type 2 diabetes, anorexia nervosa, bulimia or cachexia induced by AIDS or cancer or trauma.

37. A method of determining the nature or degree of body weight and/or eating dysfunction in a human or animal subject, the method comprising:

(a) establishing a paradigm in which at least one protein is differentially expressed in relevant tissue from, or representative of, subjects having differential levels of body weight and/or eating function;

(b) obtaining a sample of the tissue from the subject;

(c) determining the presence, absence or degree of expression of the differentially expressed protein or proteins in the sample; and

(d) relating the determination to the nature or degree of the body weight or eating dysfunction by reference to a previous correlation between such a determination and clinical information.

35

39. The method of claim 37, wherein the sample is a tissue sample or a body fluid sample.

40. The method of claim 37 or claim 39, wherein the sample is a tissue sample or a body fluid sample, and differentially expressed proteins in the sample are used to predict the nature or degree of the body weight or eating dysfunction.


41. The method of any one of claims 37 or 39, which further comprises determining an effective therapy for treating the body weight or eating dysfunction.


42. A method of treatment by the use of an agent that will restore the expression of one or more differentially expressed proteins in the body weight or eating dysfunction state to that found in the normal state in order to prevent the redevelopment of obesity in body weight reduced previously obese subjects.


43. A method whereby the pattern of differentially expressed proteins in a tissue sample or body fluid sample or urine of an individual with body weight eating dysfunction is used to predict the most appropriate and effective therapy to alleviate the body weight or eating dysfunction state and to monitor the success of that treatment.

44. A method of claim 41 whereby the body weight or eating dysfunction state is obesity.















FIG. 1E





# Liver molecular markers related to the obesity state (LOM)

Lean

Obese

LOM16



LOM17







Fig  
a

Lean

Obese

LOM18



LOM19







Fig  
3

8732

Lean

Obese

LOM20



LOM21









Fig  
4

Lean

Obese



LOM23

Fig  
5

Lean

Obese











Fig  
6

Lean

Obese





LOM27

Fig



Lean

Obese

LOM28



LOM29








# Muscle molecular markers related to the obesity state (MOM)

Lean

Obese

MOM32



MOM33









Fig. 1

Lean

Obese




MOM35



Lean

Obese





Fig



15

# White adipose tissue molecular markers related to the obesity state (WOM)

WOM37





WOM38





Lean

Obese





WOM40





Lean

Obese



WOM42




Fig

Lean

Obese




WOM43





WOM44

WOM45





Lean

Obese





WOM51





Lean

Obese



WOM48  
+  
WOM49









Fig  
1

Lean

Obese




WOM53




Lean


Obese



WOM55



WOM55



WOM56



Lean

Obese

WOM57







Fig 2c

Lean

Obese



WOM59







Fig 21



26735

Lean

Obese




WOM61




Lean

Obese



WOM102



WOM102





WOM63  
+  
WOM64





# Brown adipose tissue molecular markers related to the obesity state (BOM)

BOM66



BOM67







Lean

Obese

BOM68



BOM69








Fig 23


30133

Lean

Obese




BOM71





Fig

Lean

Obese



BOM73





32133



Lean

Obese

BOM74



BOM75




Fig

Lean

Obese

MelView

EE



BOM77

